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ABSTRACT 
The hypothesis of this work was whether IGRT could be safely implemented for clinical 
use in a busy oncology centre. I aimed to study a number of questions that remain 
unresolved in the current literature regarding safe and optimised implementation of 
IGRT techniques.  
The first study undertaken was the calculation of a local set up margin using two widely 
recognised margin recipes. This involved the assessment and analysis of multiple 
images belonging to 100 patients. This allowed progression onto the next project which 
was assessment of the optimal safe method of delineation of 4DCT. The most efficient 
method was compared to gold standard. 
At this point a different aspect of the radiation process was assessed, namely 
verification. A feasibility study of a simple, efficient form of imaging for use in review 
of a particular error was performed. This also involved the use of a novel tool which 
required independent assessment. This progressed into a further study of a larger 
number of patients using this tool and the images assessed previously to verify a novel 
form of radiation delivery. 
Lastly a planning study was performed to quantify the clinical benefit of another 
delivery system. This involved the delineation and planning of a large number of radical 
lung patients with standard radiation treatment and the novel radiation treatment and 
an assessment of the potential clinical benefits.   
The work presented in this thesis has answered some specific questions in IGRT in lung 
cancer, and contributed both locally and in the wider lung cancer community to 
increasing the use of IGRT in lung cancer.  
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1. INTRODUCTION TO LUNG CANCER AND LUNG CANCER RADIOTHERAPY 
 
1.1 Introduction to Lung Cancer 
 
1.1 Lung Cancer  
 
Lung Cancer remains the UK’s commonest cause of cancer death accounting for 1 in 5 
deaths. In the UK, around 35,000 people die from lung cancer annually, with around 
41,000 diagnoses. It is the second most common cancer in men after prostate and the 
third most common cancer in women after breast and bowel cancer [1]. Rates of lung 
cancer in Scotland are among the highest in the world, reflecting the high smoking 
prevalence [2]. Other factors such as poor diet, exposure to industrial carcinogens and 
air pollution may also contribute [3,4]. In addition, in the West of Scotland, about 6% of 
male lung cancers are attributed to asbestos exposure associated with the ship-building 
industry [5]. There is a large population of deprived patients with multiple co-
morbidities making treatment more challenging and long term survival more difficult to 
achieve [6].  
 
Treatment is dictated by the tumours pathology and staging. There are other factors 
such as performance status, co-morbidities, previous medical diagnosis, previous 
treatment and pulmonary function tests that are all taken into consideration in the 
treatment decisions; however these are individually assessed in each case as they can 
vary widely.  
In terms of pathology, this work will concentrate on non-small cell lung cancer, the 
main types of which are squamous cell carcinoma, adenocarcinoma and large cell 
carcinoma. Although the pathology of a NSCLC tumour is increasingly being used to 
dictate systemic treatment options with chemotherapy and biological agents, in 
radiotherapy, all pathological sub-types are treated with the same radiotherapy 
techniques.  
Staging is determined by diagnostic imaging with computed tomography (CT), positron 
emission tomography (PET) and histological sampling of lymph nodes where necessary 
- 2 - 
with either transbronchial approach or at mediastinoscopy [7,8]. Staging is reported 
according to the International Staging System, first published in 1986 by the American 
Joint Committee on Cancer (AJCC) and the Union Internationale Contre le Cancer 
(UICC) [9]. Table 1-1 shows the international staging system for lung cancer. 
 
 
1.1.2 Management of NSCLC.  
 
In NSCLC, only patients with Stage I-IIIB can receive treatment with curative intent. 
This study concentrates on this group. These patients have a primary tumour with or 
without local nodes all of which can be encompassed within a radiotherapy field.  
 
The gold standard management of Stage I and II NSCLC is radical surgery, with 5-year 
survival in pathologically staged patients with Stage IA, IB, IIA and IIB patients reported 
as 74%, 58%, 46% and 36% [9]. Unfortunately due to a number of issues, particularly 
poor pulmonary function and co-morbidities, the British resection rate is only 11% [10]. 
For medically inoperable patients, conventionally conformal radiotherapy is the 
standard of care in the UK and produces 5-year survival rates of between 0-42% [11]. As 
these patients are often frail with multiple co-morbidities, a different endpoint is often 
used: local control rate. The local control rate is a measure of the number of patients 
who have no recurrent disease either in the area irradiated, the surrounding normal 
lung or the regional lymph nodes. The local control rate in Stage I/II NSCLC patients 
treated with conformal radiotherapy is 30-94% [11]. There is however international 
agreement that for small tumours with no lymph node involvement, stereotactic body 
radiotherapy (SBRT), which has local control rates of 91.8%, 95% and 93%, is the gold 
standard for medically inoperable patients in selected patients [12,13,14]. This will be 
discussed further in 4.1.1.  
 
The management of Stage III NSCLC is much less clear cut; however there is consensus 
that multimodality treatment is required. A combination of chemotherapy and 
radiotherapy are used, either concurrently or sequentially occasionally with the 
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Table 1-1. The international staging system for NSCLC, 2009.  
 
  T1a Tumours ≤ 2cm 
  T1b 
 
Tumours > 2cm to ≤ 3cm 
 
  T2 Tumour involves the main bronchi; Tumour has caused partial collapse of a lobe;  
The tumour has grown into the inner lining of the visceral pleura;  
The primary tumour falls into the size categories below: 
   T2a Tumours > 3cm to ≤ 5cm 
   T2b 
 
Tumours > 5cm to ≤ 7cm 
 
  T3  Tumours > 7cm; Additional tumour nodules in primary lobe;  
Any tumour < 2cm from the carina. 
  T4 Additional tumour nodules in ipsilateral lung; Tumour invading mediastinal structures. 
  
  N0 No involved lymph nodes. 
  N1 Involved hilar lymph nodes. 
  N2 Involved mediastinal lymph nodes. 
  N3 Involved contralateral lymph nodes. 
  
  M1a Additional tumour nodules in contralateral lung; Malignant effusions; Pleural nodules. 
  M1b Distant metastatic disease outwith the lung / pleura. 
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  Stage IA 
 
T1a N0 M0; T1b N0 M0 
  Stage IB T2a N0 M0 
 
  Stage IIA 
 
T1a N1 M0; T1b N1 M0; T2a N1 M0; T2b N0 M0 
  Stage IIB 
 
T3 N0 M0; T2b N1 M0 
 
  Stage IIIA Any T N2 M0; T3 N1 M0; T4 N0 M0; T4 N1 M0 
  Stage IIIB  
 
Any T N3 M0; T4 N2 M0 
 
  Stage IV Any T Any N M1 
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addition of surgery on completion. In our centre and throughout the UK, radical chemo-
radiotherapy is treatment of choice. For a selected group of fit patients, concurrent 
chemo-radiotherapy provides a 5-year overall survival benefit of 4.5% over sequential 
treatment [15], however for those patients with large tumour bulk or who are less fit, 
sequential treatment is delivered. Irrelevant to whether the patient receives sequential 
or concurrent chemo-radiotherapy, the radiotherapy remains the same.  
 
The dose prescribed in our centre and most commonly in the UK for radical 
radiotherapy in all stages, is 55Gy in 20 fractions over 4 weeks which most oncologists 
believe is biologically equivalent to a dose of approximately 64Gy in 32 fractions over 6 
½ weeks. Most centres worldwide however, deliver 2Gy doses daily to 60-66Gy in node 
positive disease and significantly higher doses to Stage I tumours using SBRT which will 
be discussed in the next section. There have only been three, large, phase III, dose 
comparison trials ever conducted [16,17,18]. These can be interpreted in many ways, 
however the widely accepted conclusions are that in 2Gy fractions, the dose must be 
≥60Gy.  
 
 
1.2 Current Radiotherapy techniques 
 
1.2.1 CT Simulation 
 
The CT simulator is a conventional diagnostic CT scanner with special radiotherapy 
planning software and LASERS to aid patient set-up. To ensure what is delineated on 
the planning scan is as close to what is treated as possible, immobilization techniques 
are used. The patients are set up at every simulation and treatment session using 
Sinmed Posirest Thoracic Board (Sinmed BV, The Netherlands) and a knee support. 
Figure 1-1 shows the patient in treatment position with the thoracic board. During CT 
simulation, the patient is positioned for treatment and to reproduce the position, 
marks are drawn on skin (one anteriorly and 2 each side laterally) where lasers 
representing the treatment centre fall. At check simulation if everything lines up 
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correctly these marks are then tattooed to the patient so that during treatment, these 
tattoo’s can be used to set the patient up using the lasers. In patients known to have 
mediastinal disease 50ml intravenous iodinated contrast is administered at CT image 
acquisition to enable easier visualisation of the lymph nodes [19].  
 
1.2.2 Delineation  
 
The objective of radical radiation treatment is to treat all of the disease to a 
therapeutic dose level. This is achieved by firstly defining a planning target volume 
(PTV) by following the principles of ICRU 50/62 [20,21]. The delineation of the planned 
target volume (PTV) is performed by the clinician. There are several steps in the 
process that are all in accordance with ICRU 50 and 62. The general steps for 
delineation in lung radiation oncology are as follows:  
1) Initially the gross tumour volume (GTV) is delineated; this is the visible extent 
of the malignant tumour. In our centre different clinicians use different window 
levels however ideally a uniform window width and level is required to minimize 
interclinician variation. EORTC guidelines suggest window width = 1,600 and level 
= -600 for parenchyma and window width = 400 and level = 20 for mediastinum 
[22]. 
2) A margin for local subclinical spread of the disease is given to create the 
clinical target volume (CTV). Although this margin in lung cancer is usually 5mm, 
the most robust paper from Giraud et al. [23] suggests that the microscopic 
margin should be 6mm and 8mm for squamous and adenocarcinomas respectively. 
3) A further margin to create the internal target volume (ITV) is to ensure that 
the tumour is covered throughout the fraction as tumours can change in size, 
shape and position due to internal structure motion. In lung cancer the largest 
movement is due to respiration induced tumour motion, and hence a larger 
margin is given craniocaudally than anteriorly, posteriorly and laterally as 
respiration induced tumour motion is maximal in the cranio-caudal direction. 
4) Finally, a margin for set-up error encompassing both systematic errors, due to 
different set-up on the CT simulator, and random set-up errors that can occur on 
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a day to day basis during treatment, to create the planned target volume (PTV). 
This set-up margin can be calculated using equations by Van Herk et. al. [24] and 
McKenzie et. al. [25]. This calculation is explained and performed later on in this 
paper. 
 
In routine clinical practice in our centre, it is normal to combine some of these 
margins. The GTV is delineated and then a single additional margin that encompasses 
CTV, ITV and PTV margins is added to create the PTV. Craniocaudally 20mm is used, 
anteriorly posteriorly and in both directions laterally 15mm is used. This creates the 
PTV, which is the volume that we attempt to irradiate with between 95 to 107% of the 
prescribed dose. 
 
The technologists in the physics department delineate the organs at risk (OAR), which 
are those normal tissues that are sensitive to radiation. The dose to these organs must 
be restricted. This can usually be achieved by optimisation during planning. In lung 
cancer radiation the OAR are the normal lung, the spinal cord, the oesophagus and to a 
lesser extent the heart. In our centre, only the normal lung and spinal cord are 
delineated routinely and taken into consideration when choosing the best plan. It is not 
routine clinical practice to outline the oesophagus and heart in our centre as in the 
view of our clinicians we do not have a high rate of oesophageal or cardiac adverse 
effects. As radical treatment becomes more toxic with increased doses and concurrent 
chemotherapy, outlining of these organs will no doubt become standard as it will 
become increasingly important to alter plans to limit the dose to these organs. The 
measures that are reviewed for the lung are the V20 lung and the mean lung dose (MLD) 
[26]. The V20 lung is the volume of “normal” lung that receives ≥20Gy. The “normal” 
lung is calculated by combining the volumes of the left and right lung, then excluding 
any lung tissue that is covered by the PTV. This measure correlates with the likelihood 
of radiation pneumonitis and thereafter long term lung damage. The mean lung dose 
(MLD) is the mean dose to the left and right lung combined. The spinal cord has a 
maximum dose cut off; this is achieved by ensuring one of the beams misses the cord 
entirely.   
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Figure 1-1. The patient immobilised in treatment position with a Sinmed Posirest 
Thoracic Board. 
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 1.2.3 Planning and Plan calculation 
 
Planning of 3D conformal radiotherapy lung cancer is usually performed with three to 
five photon beams and multi-leaf collimators that allow shaping of the beams. A typical 
radical plan involves one wedged anterior beam with an anterior oblique and further 
wedged posterior oblique both on the side of the tumour. Choice of gantry angle 
depends on the position of the spinal cord in relation to the tumour as one of the 
beams must miss the cord entirely to maintain an acceptable dose. Non-coplanar beams 
are rarely used.  
Plan calculation in our centre is performed using the Varian Eclipse pencil beam 
algorithm (Version 8.6), however there are many other planning systems and different 
algorithms can be used. The plan is then optimised by adjustments to wedge angles, 
beam weights and gantry angles to cover the PTV with between 95-107% of the 
prescribed dose and limit the dose to organs at risk as much as possible. If following 
plan calculation the peripheries of the PTV are underdosed, boost fields to these areas 
can be added. The ability to create the best plan depends on the judgement, skill and 
experience of the operator. Occasionally there is no plan that maintains therapeutic 
dose within the PTV and has an acceptable OAR profile. In these cases, a number of 
possible plans with varying amounts of PTV covered or doses to OAR are created and it 
is the decision of the clinician where it is more clinically appropriate to compromise. 
Figure 1-2 shows a typical treatment plan in lung cancer radiotherapy.  
As described above, the dose prescribed in our centre for a radical treatment is 55Gy in 
20 fractions over 4 weeks or, if chemotherapy is being used concurrently, 66Gy in 33 
fractions over 6 ½ weeks.  
- 10 - 
Figure 1-2. A standard, 3D conformal radiotherapy lung treatment plan. 
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 1.2.4 Check Simulation 
 
There are three purposes of check simulation: 
1) Verification of the patient’s position at CT simulator is done by performing a 
bony match between a kV simulator image taken at check simulation, and the 
digitally reconstructed radiograph (DRR) created from the planning CT. Both 
orthogonal images for iso-centre verification and / or ‘beams-eye view’ of the 
actual treatment fields can be checked. If any shift is required this is performed. 
A number of radiotherapy departments are moving to eliminate this and move 
directly to pre-treatment verification on the linear accelerator (LinAC). 
2) To check tumour motion, an anterior-posterior fluoroscopic image is produced 
on the check simulator, and provided the tumour can be visualised on kV image, 
this allows assessment of the respiration-induced tumour motion, if tumour 
appears to move out of the PTV, re-planning is required.  
3) Finally, if all the previous checks are satisfactory, the tattoos are performed 
laterally and at midline as discussed above to allow set up with lasers during 
treatment.  
 
 
1.2.5 Treatment and Verification 
 
Patients are immobilised as on the CT simulator and aligned according to tattoos and 
lasers. The treatment is delivered on a daily basis.  
Verification is required during treatment as any error in set-up may cause a failure to 
irradiate all of the disease or over-irradiation of normal/sensitive tissues. Verification 
is currently performed with images acquired using the treatment machine, taken on 
days 1, 2, 3, 8 and 15, which are matched to the DRR images using bony landmarks. Any 
deviation from the position at planning, is retrospectively considered and a shift is 
made if felt appropriate for future fractions.   
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Two different images are taken routinely, each preferred by different clinicians.  
1) Orthogonal “iso-images” are single MV exposure images in both the anterior-
posterior (AP) and lateral direction. These can be acquired for “on-line” or “off-
line” review (the difference will be discussed below). These are compared to the 
same AP and lateral DRRs created from the planning CT, that were reviewed at 
check simulation, and any major errors in patient positioning can be identified. 
These images are preferred by some clinicians because they image the whole 
thorax in order to encompass rigid structures such as the spine that can be easily 
compared to the DRR. In addition, clinicians are more accustomed to viewing and 
identifying structures in AP and lateral fields rather than oblique fields. One 
exposure of the treatment machine for the acquisition of an iso-image delivers 
around 4mSv per exposure. 
2) Another set of machine images, are “dual exposure images”. They are created 
using a combination of; a fraction of the exit dose of the megavoltage (MV) 
treatment beam, during an actual treatment; and an additional exposure after 
treatment of the same field with an additional 20mm margin. This allows the 
more heavily exposed treatment field to be seen in the context of the adjacent 
normal tissue structures. Together these two images create a “double-exposure”. 
The images can only be produced from the gantry angle of the beam, therefore 
are always beams eye view (BEV) images, as some of the image is obtained using 
the treatment beam. It is often difficult to identify structures in the double-
exposure to compare to the DRR because fields can be small and the low 
differential absorption of MV X-rays in tissue gives them a similar appearance and 
hence makes it difficult to differentiate between structures. Furthermore 
clinicians are not accustomed to looking at oblique fields.  
 
The majority of verification at present occurs “off-line”, which is a term used when the 
images are reviewed after the radiation has been delivered. During off-line 
verification, the operator takes into account all shifts from CT planning position in all 
previous fractions and generates a decision (to correct or not and if so by how much) 
for the setup of subsequent fractions. The general guideline in our centre is that if the 
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bony landmarks are misaligned by less than 5mm no action is taken, if there is a 
consistent shift of 5mm in one direction a permanent shift is made. If there are 
continued concerns about patient set-up, further iso-images can be taken. If there is 
concern that the patient is moving position daily, “on-line” iso-images can be taken. 
On-line images are those taken prior to treatment, with a shift to the DRR position 
performed prior to treatment. Although iso-image can be performed on-line, the beams 
eye view double-exposure images cannot, as they are created using the treatment 
beam. This technique has many limitations and many discrepancies remain between 
what is planned and what is delivered [27]. More rational and objective off-line 
verification approaches are the “shrinking action-level” protocol [28] or the “no action-
level” protocol [29] which have shown to reduce systematic errors more, with less 
imaging required.  Figure 1-3 gives an example of a BEV EPID image, and some MV iso-
images.   
 
 
1.2.5 Potential Errors with current radiotherapy techniques 
 
Errors are divided into systematic errors and random errors. A systematic error is an 
error that is not determined by chance but is introduced by an inaccuracy in the 
system. Systematic errors are consistent throughout the radiation treatment. A random 
error can happen during any treatment day as a result of an unforeseen difference to 
patient or treatment on that day. There are a number of potential systematic and 
random errors in lung cancer radiotherapy.  
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Figure 1-3. (a) - A BEV EPID image; (b) - An anterior iso-image; (c) - A lateral iso-image  
  
 
 
(a) 
(b) 
(c) 
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Potential systematic errors: 
1) During the CT simulation, the main possible error is an error in set-up or 
tattooing which would result in consistent incorrect set-up during treatment eg. 
CT table sag, couch sag or LASER misalignment.  
2) A number of possible errors arise from the delineation process. To understand 
these it is important to know how much of the composite margin (20mm cranio-
caudal and 15mm lateral and anterio-posterior) is derived from each of the 
individual margins for, subclinical disease (CTV), internal movement (ITV) and 
set-up errors (PTV). I will hence discuss each margin individually with the possible 
errors: 
• The GTV delineated by different clinicians can vary greatly and it has 
been shown that even experienced clinicians are capable of voluming areas 
where there is no gross tumour or omitting areas where there is gross 
tumour [30]. This would result in irradiation of normal tissue or missing 
tumour tissue. This classifies as a systematic error. It is very difficult to 
allow for this error as an addition to a margin, as although there are small 
differences in where to place a delineation line around a tumour, the larger 
differences in lung cancer arise from decisions on whether or not to include 
a lymph node that has not been biopsied. To include this in a margin is 
impossible as lymph nodes are in different positions and of different sizes. 
It is therefore not encompassed in any margin. Previously elective nodal 
irradiation dealt with this issue, however it is now thought superior to only 
include malignant nodes within the GTV. Usual practice has been to outline 
all nodes greater than 1cm. Local relapse alone in adjacent nodes following 
radiotherapy is rare [31,32], probably due to some of the surrounding nodes 
being partial irradiated in the entrance and exit beams [33]. 
• The GTV to CTV margin is currently 5mm. This margin is accepted as 
standard for ease and to allow a coherent approach. In reality, the most 
significant paper on microscopic disease in lung cancer has the margins 
being 6mm and 8mm for squamous and adenocarcinomas, respectively [21]. 
The majority of centres worldwide leave margins of 5mm, however it is 
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accepted that different patients have different degrees of microscopic 
invasion [34] and therefore as we cannot assess it in individual patients, it 
will inevitably be over or under estimated in many resulting in a systematic 
error.   
• The CTV to ITV margin used in our centre, is currently a standard 
margin that is added to all tumours. It is well accepted however that 
respiration-induced tumour motion is unpredictable and varies enormously 
between patients [35,36,37]. Hence a standard margin will result in 
systematic error due to underestimation of movement or overestimation of 
movement for the majority that are at variance with the standard 
“population-based” margin allows.  
• The ITV to PTV margin, or set-up margin, is a margin chosen by the 
radiation oncology team, based on experience and judgment drawn from 
observation and evaluation of the risk of failure and complications. This is 
currently what we use at the Beatson. It can also be calculated for an 
individual department using the McKenzie et al [23] or Van Herk et al [22] 
margin equations. There may be a systematic error introduced at this point 
if has been over or underestimated. 
• In the ICRU 62 report, there is extensive discussion on how to add these 
margins together. If simple linear addition is used, it is recognised that the 
PTV may be inappropriately large. It is up to the local radiotherapy team to 
use their experience and judgement in deciding the method of addition of 
these margins.  
3) During the plan calculation process, if an error occurred in creating the plan, 
or disseminating the information to check simulation or the treatment room a 
systematic error could occur.  
4) During check simulation again if the patient is set-up incorrectly or tattooed 
incorrectly a systematic error would be introduced. 
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Potential random errors: 
1) If the patient is set-up incorrectly on a particular day. This would result in a 
random error that fraction. 
2) If the patient’s tumour changes position over the course of four weeks of 
treatment due to re-inflation of a lung or inflammation of the surrounding normal 
lung, this is not consistently present from the beginning but could be consistently 
present towards the end of treatment therefore it could be considered both 
random or a systematic error.  
3) If the patient loses weight or relaxes into the treatment couch, this could 
cause a variation from planning and hence a random error, however as with the 
tumour migration, if this error consistently becomes a problem, it could also be 
viewed as a systematic error.  
 
Although our current technique of 3D conformal radiotherapy is relatively standard, 
section 1.2.5 highlights many limitations. The current verification technique of offline 
MV images can only reduce the systematic errors occurring due to a change in patient 
position. It does not deal with any other errors. Many of the potential errors highlighted 
above can be reduced with the use of other imaging techniques and thus the 
introduction of Image Guided Radiotherapy (IGRT). 
 
 
1.3 Image Guided Radiotherapy 
 
1.3.1 What is Image Guided Radiotherapy? 
 
Image Guided Radiotherapy (IGRT) is the use of different imaging techniques to 
improve on the three main steps of radiotherapy: delineation, planning and 
verification. IGRT can improve target coverage, and facilitates a reduction in the large 
margins, that we traditionally use to allow for unknown or large errors, with a view to 
reducing dose to organs at risk (OAR). It can also facilitate alternative planning and 
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delivery techniques allowing us to escalate the dose and thereby improve the chance of 
local control.  
A number of developments in radiotherapy have emphasised a need for improved IGRT: 
• Planning has become more conformal with the advent of intensity modulated 
radiotherapy (IMRT), arc therapy such as RapidArc (Varian Medical Systems, Palo 
Alto, Ca, USA) and tomotherapy (Tomotherapy Incorporated, Madison, WI, USA).  
• With increasing interest in dose escalation, accurate target coverage and 
sparing of organs at risk become more important, as inaccuracies have more 
consequences with bigger doses.   
• With some of the new delivery techniques, fall off doses around the PTV are 
becoming much steeper. As the risk of missing the target becomes greater there 
is a real need to use imaging techniques maximally to target the PTV better  
 
 
1.3.2 Imaging techniques used in CT simulation and Delineation 
 
1. PET/CT 
The role of positron emission tomography (PET/CT) for evaluation, treatment and 
follow up of lung cancer patients is rapidly increasing. PET/CT scans make use of the 
fact that most lung cancers have increased activity of glucose transporters and 
increased hexokinase activity compared with normal cells. A radioactive agent, 
fluorodeoxyglucose (FDG) is delivered to the patient. Due to the increased activity of 
glucose transporters and hexokinase activity, it accumulates at a higher rate in lung 
cancer cells than the normal tissues. Images taken after FDG administration allow easy 
localisation of gross tumour as most deposits of tumour measuring around >1cm show 
up as a “hot lesion” on the scan. FDG labelled with the positron-emitting isotope F-18, 
is the radiopharmaceutical of choice for imaging lung cancer. The intensity of a “hot 
lesion” on PET, represents the FDG uptake and can be quantified using the 
standardized uptake value (SUV). The SUV is derived by dividing the concentration of F-
18 in the tumour, measured in Bq/gm, by the injected activity per unit body weight.  
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In NSCLC, PET/CT is increasingly used in a number of settings:  
a) To evaluate undiagnosed pulmonary masses, with 96.8% and 77.8% specificity 
and sensitivity respectively [38]. 
b) To stage NSCLC in the mediastinum with a view to dictating therapy as there is 
90% specificity and 85% sensitivity in the mediastinum [39].  
c) To detect distant metastatic disease to prevent radical treatment when it is 
inappropriate, PET/CT can identify distant metastasis in an additional 12% of 
patients who have been staged with Stage I disease with all other standard 
imaging techniques [40]. 
d) To predict response following radical radiotherapy or chemoradiotherapy [41]. 
e) The SUV level can be used as a prognostic indicator [42]. 
f) For use in the delineation process, described in detail below.  
 
The use of PET/CT in the delineation process is becoming more prevalent although 
there are a number of unresolved issues and significant potential for further 
development. In routine clinical practice, the majority of clinicians use it as a tool to 
localise areas of gross tumour. There is good evidence that the use of PET/CT for 
localisation can both increase and decrease volumes [43]. This is logical because 
PET/CT can both upstage and downstage mediastinal lymph nodes. In addition it can 
assist in deciding how much opacified lung is active tumour and how much is collapse or 
consolidation. Its use has also been reported to reduce interclinician variations in 
delineation [44] and a further paper compared PET/CT delineations to pathological 
specimens and found that using the additional information of a PET/CT improves target 
coverage from 75% to 89% [45]. There are three different ways that the PET/CT can be 
used for localisation:  
a) PET/CT and planning CT can be co-registered so that they are portrayed 
simultaneously at the planning computer terminal however due to the concerns 
regarding image registration and spatial resolution this is not available in all 
centres.  
b) A PET/CT scan can be used as a planning scan if the CT component is of an 
acceptable quality, however many patients in the UK continue to receive 
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sequential chemo-radiotherapy and it is not possible to perform a planning 
PET/CT after neo-adjuvant chemotherapy due to inhibition of SUV uptake by the 
tumour stunning.  
c) Most centres have the PET/CT and the planning CT on adjacent computer 
screens and try to relate in information of the PET/CT onto the planning CT.  
 
Another way in which PET/CT can be used for delineation is for automatically outlining 
the GTV using image segmentation methods that have primarily been based on either a 
threshold value (a percentage of SUV max) [46] or as an absolute SUV [47]. However 
consensus over an absolute ideal value has not been reached. A further limitation is 
that all image segmentation tools require clinical review and adjustment afterwards, 
reducing the time saving benefits offered by image segmentation.  
 
Finally there is much interest in the possibility of “dose painting” [48]. NSCLC are 
heterogeneous and there is evidence confirming that areas of higher SUV uptake are 
the areas where local relapse is more likely [49]. Dose painting involves using a PET/CT 
during planning to deliver a bigger dose to those areas with higher SUV levels. An 
alternative approach uses data from a PET/CT scan towards the end of radiotherapy 
treatment and delivering a boost of radiotherapy to the areas with highest SUV levels 
[50]. 
In summary, there is little controversy regarding the use of PET/CT to aid gross tumour 
localisation and there is evidence confirming the benefits, however other uses of 
PET/CT in delineation continue to be research based and should not be used out with 
that setting.  
 
 
2. 4DCT simulation 
Four-dimensional CT (4DCT) or respiration-correlated CT scan is a single investigation 
generating spatial and temporal information on mobility [51,52]. It permits organ 
motion to be observed and quantified. Previously the CTV to ITV margin was a set, 
population based margin, added arbitrarily to all patients. However as discussed above, 
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it is well recognised that the intra-fraction tumour motion of each patients’ tumour 
cannot be predicted. With a 4DCT, the intra-fraction tumour motion can be visualised 
and therefore an individualised margin, specific for each tumour, can be added. 4DCT 
has been shown to be a better method of assessing respiratory movement than 
previously used fluoroscopy [53] or the use of six, standard 3DCT’s, in combination 
[54]. The use of 4DCT to individualise the CTV to ITV margins has been shown to 
improve tumour localisation and potentially decrease normal tissue irradiation [55]. It 
is therefore an imaging technique that can assist with delineation and an important 
tool in IGRT. 
 
There are multiple commercial hardware and software packages available to perform a 
4DCT. I will describe the Varian Medical Systems software that was used for this 
research as it is available in both centres where this research was undertaken.  
To create a 4DCT scan, a respiratory trace is recorded throughout the scanning process 
and saved independently. This trace is the anterior-posterior movement of the chest 
wall captured by an infra-red marker box positioned on the xiphesternum. This infra-
red marker box and its anterior-posterior motion is an external surrogate of the 
superior-inferior internal tumour motion. The CT scanner images a 20cm length of the 
thorax for the duration of a respiration cycle and takes 10 consecutive scans over one 
respiration cycle. The bed then moves and the next section of lung is scanned in 
exactly the same way. The different scans are divided into 10 “bins” relating to 10 
sequential phases of the respiratory cycle. These are labelled 0%, 10%, …. ,  90%. The 
0% phase usually lies closest to maximum inhalation and maximum exhalation usually 
lies around 50%. In basic terms the respiratory trace is a sine wave. The clinically 
relevant parameters are the amplitude, which can increase or decrease depending of 
the depth of the patients breath; and the wavelength, which can increase or decrease 
depending on the rate of respiration. The ideal is to have regular breathing both in 
terms of wavelength and amplitude, unfortunately breathing patterns are seldom 
regular in patients with poor pulmonary function, thus there is interest in identifying 
the potential impact of coaching, on image quality and target coverage. There are  
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Figure 3-2. An illustration of the Varian RPM system. 
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different methods of coaching a patient, for example, audio or visual or a combination 
of both. In addition, patients can undergo monophasic or biphasic coaching. During 
monophasic coaching only inspiration or expiration are prompted versus biphasic 
coaching where both inspiration and expiration are prompted. There are numerous 
papers looking at the benefits of coaching. All forms of coaching are shown to improve 
the regularity of the wavelength and the amplitude of the respiratory trace by varying 
degrees [56]. Whether it is the wavelength or the amplitude that are more consistent is 
important for different reasons.  
During acquisition of the 4DCT planning scan, a consistent wavelength allows a better 
image. Improving the consistency of the amplitude of the respiratory trace, is not 
useful in improving image acquisition. However, if there is abnormally large movement 
amplitude during the recording of the respiratory trace in 4DCT, it may not represent 
the amplitude of tumour motion on treatment. If coaching is introduced during the 
planning scan in order to maintain constant wavelength, in theory coaching would have 
to happen during treatment in order to maintain the coaching amplitude. However 
introducing coaching for this theoretical risk, one has to be aware there are concerns 
coaching can increase the tumour amplitude which would translate into larger volumes 
and more toxicity [57]. This study suggested that a coached 4DCT could not be used 
when there is no coaching performed during treatment [54]. However on review of the 
study, it reported a mean increase in PTV of 10.2%, which from our own work, 
correlates with an increase in V20 of around 1-2%. This increase in V20 is extremely 
unlikely to be clinically relevant. The same paper suggests that there is a different 
centre of mass (COM) for the ITV delineated in coached and free breathing scans. The 
COM varies by a mean of 2.7mm. It is not described in which axes this movement occurs 
nor whether it is primarily in one direction or divided amongst the six directions. It is 
unlikely motion of this magnitude would result in any clinical consequence. As the 
evidence currently stands, there is no evidence that coaching at 4DCT to obtain a 
better image and not coaching on treatment will cause any clinical detriment to the 
patient. 
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It was hoped that coaching during treatment delivery would decrease the variability of 
the tumour amplitude and hence improve target coverage [58]. However the studies 
undertaken demonstrate a reduction in the variability of the external surrogate, not 
the internal tumour movement, and these do not necessarily correlate. It remains 
unproven whether coaching reduces the variability of the tumour amplitude. 
Respiratory gated radiotherapy is a different situation. This is when the radiation beam 
is switched on during one phase of the respiratory cycle. As the radiation beam requires 
a regular breathing cycle to switch on and off, a regular wavelength is a paramount 
therefore in respiratory gated radiotherapy, therefore coaching is recommended. 
In summary, although coaching can improve consistency of wavelength and amplitude, 
and hence improve the image acquisition, there are concerns regarding its use and no 
evidence it results in improved target coverage outcome other in respiratory gated 
radiotherapy where it is recommended. Further investigation into the benefit of 
coaching in non-respiratory gated radiotherapy patients is required. 
 
The 4D software is also used to create a Maximum Intensity Projection scan (MIP), an 
Average Intensity Projection (Ave-IP) and a Minimum Intensity Projection (Min IP) from 
the raw data. In these datasets, each pixel is assigned the highest (in the MIP), the 
average (in the Ave-IP) or the lowest (in the Min-IP) density value that occurred, taking 
account of all 10 scan phases. For a solid tumour moving within low density lung tissue, 
the MIP gives a good representation of the volume occupied by the tumour throughout 
the respiratory cycle, while the Ave-IP is the data-set appropriate for calculation as it 
represents the lung volume in its average position. Figure 1-4 demonstrates the 
difference between the different constructed image-sets. 
There is great controversy regarding the best method of delineating from a 4D scan due 
to abundance of data-sets there are to deal with. This will be discussed further in 
Chapter 2. 
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Figure 1-4. Image demonstrating the different constructed image-sets: (a) 
demonstrates the different “bins” representing different phases of the respiratory 
cycle; (b) A Maximum Intensity Projection (MIP) which is where the highest density 
pixel is selected for the image-set; (c) A Minimum Intensity Projection (Min-IP) which is 
where the lowest density pixel is selected for the image-set; (d) An Average Intensity 
Projection (Ave-IP), where the average density pixel is selected for the image-set 
 
 
 
 
 
(a)                      (b)      (c)                      (d) 
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In 4DCT the traditional labels of GTV, which is enlarged to CTV, then ITV then PTV are 
no longer appropriate. On a 4DCT, there are a number of methods of delineating 
however the following volumes are commonly created using a 4DCT:  
• The Gross Internal Tumour Volume (GITV) is the gross tumour in all phases of 
the respiratory cycle. 
• The Clinical Internal Target Volume (CITV) encompasses the CTV in all phases of 
the respiratory cycle.  
Whether the 5mm margin for microscopic invasion is added before or after the internal 
target motion will vary depending on the software available to the clinician, and 
clinician preference. The final margin applied is the set up margin from CITV to PTV. 
Figure 1-5 demonstrates the traditional labelling of structures, and the labelling of 
structures that will be used when there is discussion of 4DCT. 
 
 
1.3.3 Imaging techniques used in Verification 
 
There are 2 new radiotherapy verification developments in lung cancer.  
1) The first is the development and use of novel image types to allow for easier 
verification of structures and better matching. These include kV imaging, 
fluoroscopy, CBCT, and MV-cine. Kilovoltage imaging and fluoroscopy have been 
traditionally been used in check simulation, but they can now be produced on the 
treatment machine using an imager which is attached to the linear accelerator. 
This treatment machine imager also allows the acquisition of cone-beam CT (CBCT) 
scans. These scans permit the 3-dimensional verification of the position of the 
tumour and surrounding organs at risk [59]. MV-cine are a number of BEV frames 
captured using the treatment beam run together to create a cine-image of the 
tumour during the treatment delivery [60]. 
2) The second is that there is now hardware and software to allow easy on-line 
image acquisition, review and set-up modification prior to treatment. Images of the 
patient, taken using treatment machine imagers attached to the radiation 
treatment machines are taken immediately prior to treatment. These are then 
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reviewed and matched to the planning DRR. Lastly immediately prior to treatment, 
a shift is made so that all systematic and random errors, in their traditional sense, 
are minimised. The patient is then treated.  
 
In the current era of lung oncology, potential errors cannot be easily explained or 
understood using the traditional description of systematic and random errors, as 
explained above. Delivery errors are better divided into 4 categories which can have 
systematic or random components. They have been divided in this way so that the 
different imaging techniques, suitable for each error, can be discussed individually. 
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Figure 1-5. The image on the left demonstrates the terms dictated by ICRU 50 / 62 that 
are commonly used. The image on the right demonstrates the terms that will be used 
when discussing volumes delineated using a 4DCT. 
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1. Interfraction Patient Motion (set-up error) 
Because immobilisation is imperfect, the patient will lie in a slightly different position 
every day. If this varies day to day during treatment, this is a random error whereas, if 
the patient lies in a consistently different position during planning and treatment this 
would result in a systematic error. More difficult to classify is if the patient begins to 
relax into the bed over the course of 4 weeks of radiation resulting in a consistently 
posterior set-up, this is probably best clarified as a newly acquired systematic error. 
Daily online matches to minimise interfraction patient set up error could be done with:  
1) A pre-verification MV iso-image, as discussed above, which delivers an additional 
dose of 4mSv. 
2) A CBCT which delivers a dose of 45mSv. 
3) A pair of static orthogonal kV images which deliver only 0.2mSv.  
The newly acquired image can then be initially automatically matched using stable 
bony anatomy, such as the spine, to the planning DRR and then manually verified. The 
shift required to have the patient in the planning scan position is highlighted in the 
control room and when approved, the shift is made to the treatment bed. All 
corrections are limited by the image quality and the ability of the operator to 
perform/confirm the match. Figure 1-6 demonstrates a CBCT image and a pair of kV 
orthogonal images. Figure 1-3 is an example of MV images. 
Prior to the introduction of treatment machine imagers, if on-line matching was 
required, MV images were traditionally used as it was only possible to create MV images 
using the LinAC. However MV radiation is absorbed via the Compton Effect and the 
uniform absorption makes it difficult to differentiate the stable bony structures such as 
the spine from the soft tissues. The harder it is to pick out the stable bony structures, 
the more difficult either an automatic or manual match is to make. There are now good 
comparative studies of MV images versus both CBCT and kV orthogonal images for set-
up. These have consistently demonstrated inferiority of MV images and hence MV 
images do not have a role in interfraction patient motion [61]. 
When comparing kV orthogonal images to CBCT for on-line set up, they were found to 
be equally as good at matching to DRR in all planes, however correction of rotational 
errors remains superior with CBCT [62]. Rotational errors cannot be adjusted for on the 
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treatment unit, so if a rotational error of >2-5 degrees is noted, the patient would be 
repositioned and a further on-line image taken. As a result, other than with rotation 
that cannot be adjusted for, CBCT and kV orthogonal images are equally as good for 
reducing interfraction patient motion or set up. Due to the radiation dose of kV 
orthogonal imaging being lower, kV orthogonal images should be used for daily on-line 
set up as it delivers far less dose.  
 
Daily on-line set up with kV images minimises the systematic and random errors present 
due to changed patient position, however many departments cannot image daily due to 
time constraints. Different imaging protocols include: on-line imaging daily for the 1st 5 
days only, online imaging days 1-5 then weekly, online imaging weekly or on alternate 
days. An off-line protocol must then be implemented for the days that on-line imaging 
does not take place. An off-line protocol will reduce the systematic error however the 
random error will only be minimised the days an on-line image is performed. There is 
no consensus on which of these protocols is the best in reducing systematic set-up 
error. Higgins et al. recently published a paper comparing these off-line protocols. 
They compared daily online imaging, imaging the first 5 days, imaging weekly and 
imaging alternate days. They confirmed that daily online set-up can allow set up 
margins of 3-4mm and significantly reduces random set-up. Of the other imaging 
protocols, which only dealt with systematic error and do not make any difference to 
random error, an average of the 1st 5 days had unfavourable levels of geometric 
uncertainty in comparison to the weekly or alternate days protocol, which reduced 
systematic errors so that a set-up margin of 5mm could be used [63]. Further research 
is required to confirm the best imaging protocol. 
 
In summary, kV orthogonal images are most suitable imaging technique for the 
interfraction patient motion error. As they deliver minimal radiation exposure it is 
possible to undertake online daily imaging which is effective at minimising both 
systematic and random set-up error. 
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2. Interfraction Tumour Motion (tumour migration and volume change) 
Tumour migration and volume change during the course of 4-6 weeks of radiation is a 
recognised phenomenon. This migration can be an increase in the volume, a decrease 
in the volume or a migration of the centre of mass as a result of many factors for 
example weight loss, inflammation or re-expansion of a lung. In terms of tumour 
migration: Sonke et al. report that the mean interfraction tumour migration of the 
volumes was 1.6mm (left-right), 3.9mm (cranio-caudal) and 2.8mm (anterior/posterior) 
[64]; Britton et al. results were not too dissimilar with migration of the tumour volume 
reported as 3mm (left-right), 5.4mm (cranio-caudal) and 4.5mm (anterior/ posterior) 
[65]. In terms of changes in tumour volume: Erridge et al. showed that in a population 
of 25 patients, tumour shrinkage of at least 20% occurred in 40% of the patients [66]; in 
Britton et al volume loss of at least 40% occurred in 50% of the patients; Bosmans et al 
report a 30% reduction in 13% of patients and a >30% increase in tumour size in 17% of 
patients [67]. There are other reports of volumes increasing over the course of 
radiotherapy, Underberg et al. reported an initial increase in tumour volume of 10cm3 
in at least 2 of 40 patients [68], however the incidence of increase in tumour volume 
does appear to be less than the incidence of tumour volume reduction. 
Another form of interfraction tumour motion is baseline shifts where end-inspiration 
and end-expiration position varies. Sonke et al. reported the largest study looking at 
this specific error in 56 patients. They found the systematic average baseline variations 
were 1.6, 3.9, 2.8mm and the random baseline variations 1.2, 2.4, 2.2mm in left-right, 
craniocaudal and anterior-posterior directions respectively [69]. The baseline shift is a 
difficult error to visualise and therefore monitor. As a result of this, Sonke et al. 
developed the 4D-CBCT, which is an online image which gives all the information of a 
CBCT with additional information on baseline shift and intrafraction tumour motion 
(respiration motion) [70]. It is currently unknown whether baseline shifts in an external 
structures correlate with baseline shifts in the internal tumour and this requires more 
investigation. This error becomes of more significance in respiratory gated radiotherapy 
where the aim is to irradiate in either end-expiration or end-inspiration. 
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Figure 1-6. (a) Three slices through a CBCT with the planning GTV superimposed, (b) A 
pair of orthogonal kV images with the structures from the planning DRR superimposed. 
 
(b)  
(a)  
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Each of these potential interfraction tumour motion errors can only be highlighted by 
CBCT. CBCT allows visualisation of the tumour bulk, and therefore enable a check to 
ensure there has not been significant alteration the tumour bulk or position from the 
planning scan. If either has occurred, the patient requires re-planning to prevent 
geographical miss. CBCT is the only imaging technique that gives an accurate position 
and size of the tumour and therefore should be incorporated into all verification 
protocols to check for interfraction tumour motion error. There is no evidence 
supporting daily imaging to identify interfraction tumour, the feeling is that CBCT can 
be used once or twice a week to identify any concerns however the ideal frequency of 
CBCT requires further investigation. A number of groups have suggested that in Stage I 
tumours doing a soft tissue match onto the tumour would reduce the errors that occur 
due to tumour migration [71,72], however on the other hand, in node-positive tumours, 
there are concerns that soft-tissue matching contribute further errors and hence are 
best avoided [73].  
 
Using CBCT to identify patients where the tumour volume has altered or moved has 
raised the possibility of adaptive planning, i.e. altering the volume or plan to allow for 
these changes. Britton et al. repeated 4DCT planning scans on 10 patients undergoing 
radiotherapy and found that when the original plan was recalculated on the repeat 
4DCT’s, as a result of changes in tumour volume, mobility and patient set-up, 
occasionally there were dramatic dosimetric consequences [74]. There has been 
enthusiasm in some areas for reducing volumes in those patients whose tumours have 
shrunk, in order to spare normal lung by reducing the V20 during the radiation [75] 
however, there are some widely felt concerns regarding this. The reluctance to 
embrace this technique is because it has been shown that non-small cell lung cancer 
stem cells are radioresistent [76] and although the tumour bulk may have reduced, 
there may be a small number of radioresistant stem cells that cannot be visualised by 
the repeat imaging. By reducing the volume, these radioresistant cells may lie, unseen, 
outside the new gross tumour volume. By irradiating the most resistant cells to a lesser 
dose you increase the likelihood of local relapse. Consequently, replanning due to 
marked increase or migration of tumour volume, or patient set-up or body habitus may 
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reduce toxicity in the minority of patients who would suffer dosimetric consequences 
due to these events [70]. However adaptive planning following tumour shrinkage should 
be used with caution and only within clinical trials.  
 
In summary, in node-positive tumours, once or twice weekly online CBCT with a bony 
match, can be used in to highlight those patients who have suffered a significant 
increase in tumour size, or tumour migration, so that a repeat 4DCT can occur for re-
planning. If the tumour reduces in size, replanning would not be advised in these 
patients. In Stage I patients, online CBCT can be used for a soft tissue match.  
 
3. Intrafraction patient motion (patient moving during treatment) 
While the patient lies on the treatment bed, there is some intrafraction patient 
movement. The intrafraction patient motion increases as the treatment time increases. 
Purdie et al suggested that any treatment taking more than 30 mins would require a 
further on-line image because after 34 mins, the intrafraction tumour position 
deviations changed from being 2.2mm, which was considered acceptable due to their 
3mm action level, to >11mm which was considered unacceptable [68]. Hoogeman et al 
reported that the standard deviation (SD) of the intrafraction displacements increased 
linearly over time. The SD increased to 0.8, 1.2, 2.2mm respectively in a period of 15 
mins [77]. As margins are getting smaller and especially in very conformal treatment 
such as stereotactic radiotherapy, these small errors become more important to 
quantify to ensure target coverage. 
 
4. Intrafraction tumour motion (respiration-induced tumour motion) 
This is primarily the respiration-induced tumour motion during the radiation treatment. 
There is also a degree of intrafraction motion as a result of hysteresis and heart 
motion. Hysteresis is difference between the inhalation and exhalation trajectory of 
the tumour [78]. The challenge with intrafraction tumour motion is that it can vary 
from day to day, week to week. A single assessment of intrafraction motion is captured 
in a “snap-shot” 4DCT scan. This is described as a “snap-shot” because although 4DCT 
gives the additional dimension of time, the period of time it takes to scan the primary 
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tumour with motion is only for the duration of one respiratory cycle. However what is 
imaged on the 4DCT at simulation may or may not be the same respiration-induced 
movement and hysteresis that occurs during treatment. If the average movement and 
hysteresis is captured during the planning, and during any fraction of treatment there is 
slightly more or less movement than the average, this would be considered a random 
error and it is unknown if this would have clinical consequences. If during the 4DCT 
planning scan there is less or more tumour motion visualised than normal, the margin 
will consequently be either too big or too small, resulting in a systematic error. As a 
result the target would be consistently missed or normal tissue consistently irradiated, 
which is more likely to have a clinical consequence. There are a number of techniques 
that can be used to ensure that what is visualised during the CT planning scan is what is 
occurring on the treatment room.  
1) Abdominal compression is designed to reduce the respiration induced motion so 
that it is kept at a minimum both during planning and subsequently during 
treatment. This compresses the abdomen, reducing the tidal volume and hence the 
intrafraction tumour motion [79,80]. However, the American Society for 
Therapeutic Radiology and Oncology state as a pre-requisite to immobilization in 
SBRT patients, that patients need to be able to lie comfortably despite their 
immobilization technique. It is recognised that patients feel less comfort with an 
abdominal compression frame in place. In addition, a recent paper has confirmed 
that although abdominal compression reduces motion, it increases the variation in 
the intrafraction tumour motion and therefore is not as suitable a method of 
managing intrafraction patient motion as previously thought [81].  
2) CT scans undertaken during breath-hold have been mentioned in the literature 
[82]. This is used mainly in centres without 4DCT with the aim of capturing tumour 
in a stable position (a specific respiratory “gate”). This allows planning and 
treatment during breath hold with the aim of irradiating while the tumour is not 
moving thus removing the uncertainty of a population based margin or potentially 
decreasing the normal tissue irradiation. However as we have a 4DCT, the 
reproducibility of a breath-held CT on treatment is subject to a great deal of error 
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[83] and we have a population with significant co-morbidity who are not likely to 
tolerate breath hold, this is not something we plan to investigate.  
3) The use of a single “snap-shot” 4DCT can produce random or systematic errors if 
the intra-fraction motion during treatment is different to that visualised at 4DCT 
planning. There are a number of papers that look at the likelihood of a systematic 
intrafraction tumour motion error. Michalski et al. reported tumour motion 
reproducibility of 87% and suggested rechecking the intrafraction tumour motion at 
some point after 4DCT to highlight the small proportion who had different amounts 
of movement [84], Bosmans et al. reported that although a small number of 
changes in tumour motion were seen over the course of treatment, in only 4% of 
patients this would have resulted in an increase of the internal margin [63], 
Guckenberger et al. found that the mean peak to peak tumour motion changed by 
only 0.9mm on two different scans [85], Sonke et al. reported that the mean 
variability of the tumour trajectory shape did not exceed 1mm (1 SD) [60]. These 
papers suggest that for the vast majority of patients it is safe to perform one 4DCT 
planning scan and treat without re-imaging the intrafraction motion. To identify 
the few patients who have a systematic error can be done by re-imaging the 
intrafraction tumour motion either prior to or during the first few fractions of 
treatment. 
4) Fluoroscopy can be used to make a further assessment of the intra-fraction 
respiration induced motion; however tumours are not always seen on kV images. 
Fiducials can be implanted into the tumour percutaneously or transbronchially so 
that the intrafraction motion can be monitored easily on kV fluoroscopy. However 
this is not commonly performed, as insertion can be technically difficult, there is a 
significant risk of pneumothorax [86] and there are high drop-out rates after 
bronchoscopic placement [87]. 
5) Due to the fact a CBCT image is taken over a number of respiratory cycles, it 
gives a picture of the tumour over a number of respiratory cycles i.e. it gives an 
impression of intrafraction tumour motion. The CBCT image has the high density 
tumour in the average position of the tumour, however there is varying degrees of 
density around it that can be used to either subjectively assess the tumour motion 
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when comparing the image to the Ave-IP, or objectively quantify tumour motion 
using the complicated published technique [88]. This is a quick, subjective method 
that can be used to ensure the tumour motion does not differ widely from what was 
captured at 4DCT. 
6) 4D-CBCT’s allows online visualisation of intrafraction tumour motion [90]. Sonke 
et al. found that in Stage I tumours, the systematic intrafraction motion variability 
was 1.2, 1.2 and 1.8mm and the random variation was 1.3, 1.5 and 1.8mm 
(random) in left-right, craniocaudal and anterioposterior direction respectively 
[66]. These measurements confirm that in the majority of patients there is minimal 
variation in intrafraction tumour motion, however the 4D-CBCT offers an 
opportunity to identify any outliers with more variation which may result in 
geographical miss. 
7) Many 4DCT planning scans require an external surrogate to be placed on the 
xiphisternum or the abdomen in order to create the scan. Amplitude Monitored 
Treatment Delivery (AMTD) is a novel technique developed in the VU Medical 
Centre, Amsterdam which uses the respiratory trace created using the external 
surrogate, as a surrogate for the internal tumour. AMTD is achieved by noting the 
maximum amplitude of the external surrogate cranio-caudal motion during the 
4DCT scan as an estimation of the maximum intrafraction tumour motion. If the 
external surrogate cranio-caudal motion exceeds this threshold, the treatment 
machine is programmed to automatically turn off. The problem with this technique 
is that internal structures do not necessarily correlate with external surrogates. 
Correlation coefficients between tumour and external surrogate have been 
reported as 87% in the superior-inferior direction, but as little as 44% in the 
anterior-posterior position by Koch et al. [89] and 81% in all directions by Hoisak et 
al. [90]. The lack of correlation was also confirmed by a study examining the 
residual movement within one respiratory bin over a course of treatment and 
identified it to be as much as 6.2mm [91]. Implementing AMTD is a lengthy process, 
and as the machine is turned on and off treatment can take longer to deliver, 
increasing the intrafraction patient movement and potential consequent  errors. 
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AMTD may offer assistance with target coverage that is otherwise missed due to 
intrafraction tumour motion, however this requires further investigation.  
 
 
1.3.4 Different treatment delivery techniques available as a result of IGRT 
 
1.3.4.1 Phase-Based and Amplitude-Based Respiratory Gated Radiotherapy 
With the introduction of 4DCT, there has been a great deal of interest regarding the 
possibility of using the 4DCT to plan and deliver respiration gated radiotherapy (RGRT). 
This involves treatment delivery at selected phases of the respiratory cycle which can 
be achieved using different systems. Within our institution, the Varian RPM system 
(RPM; Varian Medical Systems, Palo Alto, CA) is used. The patient’s respiration cycle is 
monitored continuously by an external surrogate; an infrared marker box placed on the 
xiphisternum. The movement of the marker box is picked up by a camera and a 
respiratory trace observed in the control room. This trace enables the selection of a 
respiratory phase or “gate” for treatment delivery and the treatment beam is switched 
on only during this interval. RGRT can be delivered in end-inspiration or end-expiration. 
There are two methods of RGRT, phase-based gating and amplitude based gating, each 
with advantages and limitations. Figure 1-7 illustrates phase-based and amplitude-
based RGRT. 
 
In Phase-based RGRT, the breathing cycle is divided into multiple time segments and 
radiation delivery is based on the same phase of the patient's respiratory cycle. The 
phases selected for irradiation are usually 90%, 0%, 10% or 40%, 50%, 60% in end-
inspiration and end-expiration respectively. The main limitation of phase-gated RGRT is 
while there may be no baseline shift in the external surrogate baseline position; 
internally there may be a baseline shift. There is no information available as to 
whether or not there is any correlation between the external surrogate baseline shift 
and the internal tumour baseline shift. Hence the tumour position during the end-
inspiration or end-expiration may differ from that  captured on the 4DCT planning scan. 
Although the treatment beam is on at the correct time, end-inspiration or end-
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expiration, the tumour position at this time could be different to that seen during 
planning.  A further possible problem is the potential for a phase-shift between the 
external surrogate and the internal tumour. This would result in the extremes of 
motion of the tumour not coinciding with the extremes of position of the external 
surrogate. If this has occurred in the planning scan and continues throughout 
treatment, it is consistent so consequently will irradiate in the correct area. If a phase-
shift occurs during treatment, but was not present at planning, in the beam would be 
switched on at the incorrect time. Spoelstra et al. used static MV images taken during 
RGRT treatment, during treatment at end-inspiration, to calculate the standard 
deviations of systematic ( ∑ )  and random ( σ ) errors in tumour position and found 
them to be 1.8mm and 1.7mm respectively [92]. This study reassures us that baseline 
shifts and phase shifts are usually limited. The study also offers a quick verification 
method to ensure the tumour is in the field by taking an MV image.  
In amplitude-based gating, treatment delivery is based on the absolute position of the 
marker block on the patient's thorax or abdomen, regardless of the phases in the 
patient's respiratory cycle. The limitation of amplitude-based RGRT is that if there is a 
baseline shift in the respiratory trace, and this does not correlate with a baseline shift 
in tumour position, the treatment beam will be switched on when the tumour is not in 
end-inspiration or end-expiration. Although there are studies looking at the dosimetric 
consequences of amplitude-based gating [93,94] there are no studies similar to the one 
mentioned above, confirming the residual motion within the treatment “gate”. 
RGRT has been shown to reduce the size of the PTV when compared to the standard 4D 
PTV [95], and there are some reports that toxicity parameters are reduced [96,97] with 
the use of RGRT although whether this represents a difference in clinical outcome and 
requires further investigation. 
 
There are further concerns regarding both forms of RGRT.  
1. One source of geometric uncertainty is the correlation between internal tumour 
motion and movement of the external surrogate when using the Varian RPM system, 
as occasionally it can be inconsistent [98]. Despite the Spoestra et al. confirming 
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minimal systematic and random residual motion, unease regarding disparities 
between external surrogate and internal tumour position remains.   
2. Respiratory coaching is advised for RGRT. It is more important to reduce 
baseline shifts in RGRT and coaching has been shown to do this. In addition, the 
treatment beam requires a regular wavelength in the respiratory cycle to turn on. 
Coaching, especially auditory, increases the regularity of the wavelength therefore 
it is advised [99,100].  
3. A further disadvantage of RGRT is that due to irradiation only proceeding 
during a specific respiratory ‘gate’ or ‘phase’, the radiotherapy beam spends 
around 80% of the respiration cycle switched off. Treatment delivery therefore 
takes longer which can in turn increase the risk of shifts in patient position [68].  
4. As well as in continuous (non-gated) 4DCT treatment as discussed above, the 
use of a single 4DCT planning scan, for RGRT can also result in systematic errors in 
the treatment plan, and random errors during treatment when what is visualized on 
the planning 4DCT is not representative of intrafraction motion during treatment 
[101].  
5. There remains differing ideas regarding whether the selected phase of 
respiration should lie in end-inspiration or end-expiration [102]. End-inspiration 
captures the lung at maximum expansion therefore potentially sparing more normal 
lung tissue [103] however the tumour remains in end-inspiration for significantly 
less time therefore there is a smaller treatment window [104] and the end-
inspiration tumour position is more variable than the end-expiration tumour 
position. In end-expiration, there is a longer treatment window, the tumour 
position is more stable, but the lung is compressed therefore more lung is within 
the treatment field. 
6. There also remains controversy concerning the threshold of craniocaudal 
tumour motion when RGRT should be considered. The AAPM recommended 
respiratory management for tumour movement greater than 5mm [105], Spoelstra 
et al. used 7.5mm, Starckschall et al. investigated if tumour motion could be used 
to predict those patients who would have the most clinical benefit however, they 
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only found a correlation between tumour motion and clinical benefit with RGRT in 
small tumours (GTV <100cm3, [91]). 
The theoretical advantages of RGRT are: reduction in toxicity; potential for dose 
escalation; and fewer patients having radical treatment withheld on account of 
large volumes or unacceptable toxicity parameters. It is an interesting concept; 
however the clinical benefit remains to be seen.  
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Figure 1-7. Illustration demonstrating the different forms of respiratory gated 
radiotherapy. 
 
 
Amplitude 
observed at 
4DCT 
(a) End-inspiration Phase-Based Gated Radiotherapy 
(c) Amplitude Monitored Treatment Delivery 
Position of external 
surrogate during maximum 
expiration  at 4DCT. 
(b) End-expiration Amplitude-Based Gated Radiotherapy. 
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1.3.4.2 Stereotactic Radiotherapy 
Stereotactic body radiation therapy (SBRT) is a newly emerging radiotherapy 
treatment, aimed to deliver a high dose of radiation to the tumour, a biological dose 
equivalent of around 180Gy, utilizing either a single dose or a small number of fractions 
with a high degree of precision [106].  
A combination of factors enables SBRT to deliver these large doses to the tumour. One 
such factor is to keep the planned target volume as small as possible, which is achieved 
by only treating tumours of <50mm in diameter and using very small, 3-5mm GTV to 
PTV margins. Another factor enabling the delivery of such high doses is the use of 
multiple fixed beams, usually 10-12 coplanar beams, with a linear accelerator so that 
the incidental dose to organs at risk in the beam projectory are not unacceptably high. 
The large numbers of beams make the isodose lines very conformal to the PTV and also 
results in very steep fall off dose gradients.  The combination of a requirement of small 
margins and the steep fall off dose gradients require the high degree of precision 
required in SBRT. This precision is achieved by the use of IGRT. Due to the minimal 
margins and high doses, SBRT requires much more stringent constraints and 
minimisation of the effects of potential geometrical errors, with appropriate audit and 
QA. An awareness and calculation of the four errors discussed in detail in section 1.3.3. 
There is no fool-proof method for infallible management or prevention or of any of the 
four errors. They are potential errors that can be managed adequately with the 
techniques discussed below. Once a centre has decided how they hope to managed 
these errors and SBRT has been implemented, they must evaluate and audit their errors 
to ensure their method is adequate. 
1) Methods to Manage Intrafraction Tumour Motion 
These are discussed in more detail in section 1.3.3. All of these methods have 
limitations but used in combination, consistent local control rates of >90%, confirm 
that these are adequate.   
• There was a great deal of interest in the Stereotactic Body Frame (Elekta 
Oncology Systems, Crawley, UK) that allows abdominal compression which 
has been proven to reduce intrafraction tumour motion. However a recent 
paper has demonstrated that the Stereotactic Body Frame with abdominal 
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compression can increase the variability in the intrafraction tumour motion 
and therefore this may not be as suitable a method of managing intra-
fraction patient motion as previously thought [76]. 
• A 4DCT to assess the normal intrafraction tumour motion and encompass 
the movement in its entirety. 
• CBCT or 4D-CBCT during online set up, where the intrafraction tumour 
motion can be assessed and the plan changed or adjusted only if the motion 
is different from what was seen at planning.  
• The RPM system which can be used to monitor the external marker as a 
surrogate of intrafraction tumour motion so that the treatment beam can 
be stopped if the surrogate demonstrates different motion than seen at 
planning.  As discussed above, the correlation is not always consistent; 
however this may be used in combination with other methods. 
 
2) Methods to Manage Interfraction Tumour Motion  
This motion is limited because a treatment course lasts no more than two weeks 
and tumours are less likely to migrate over this period of time. In SBRT, the CBCT 
that is used for set up is matched to tumour, rather than bone, so unless there has 
been a large change in position, so much so that the dosimetry is likely to be 
different, a tumour match will usually remove any error relating to interfraction 
tumour motion. If the tumour has increased in size between planning and any 
fraction, the patient will undoubtedly require re-planning to prevent under-dosing 
areas of the periphery of the tumour.  
3) Methods to Manage Intrafraction Patient Motion 
Increased treatment times result in increased intrafraction patient motion. 
Hoogeman et al. demonstrated that the SD of the intrafraction patient motion 
increased in 15 minute intervals from 0.8mm to 1.2mm to 2.2mm [73]. Purdie et al. 
confirmed this relationship by showing that the mean intrafraction patient motion 
increased from 2.2mm to 5.3mm when the treatment took over 34mins [68]. As a 
result of these studies, during SBRT where the patients are immobilized as they are 
in standard conformal radical radiotherapy, with the thoracic board and knee 
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support which is described as “frameless” SBRT, the CBCT should be repeated every 
30 minutes. As treatments take on average 45 minutes, after about 25 minutes of 
treatment it should be paused in order to acquire a further CBCT. With this CBCT a 
further online set up with shift is performed prior to continuing the treatment. 
There are some other tools produced by different manufacturers to limit this error 
which can be used. The ExacTrac System (BrainLAB, Germany) continuously 
monitors around six infrared markers on the patient’s chest wall during treatment, 
and cuts off the radiation beam if the markers move outwith the movement 
encompassed in the margin. This is thought to reduce the intrafraction patient 
motion, but at the expense of prolonging treatment. The second tool produced 
with an aim of reducing intrafraction patient motion was the Stereotactic Body 
Frame, but as discussed above reduces intrafraction tumour motion at the cost of 
increased variability. Therefore other methods which do not increase variation are 
preferable.  
4) Methods to Manage Interfraction Patient Motion 
Patient set up is of prime importance in SBRT in order to maintain the small GTV to 
PTV margins that are required. CBCT matching to tumour rather than to bony 
anatomy is required in all cases of SBRT. There has been a plethora of papers 
discussing the use of CBCT for tumour matching in SBRT and all have suggested that 
the remaining systematic errors are all within the 3-5mm margin applied [107,108].  
 
There were three original Phase II trials of SBRT in early-stage medically inoperable 
NSCLC patients [12,13,14]. Since their publication SBRT has been implemented 
worldwide and there are now numerous Phase II trials reported. All three seminal trials 
used slightly different techniques. Timmerman et al. used abdominal compression with 
a Stereotactic Body Frame with the theoretical view at the time that this would reduce 
intrafraction tumour motion and intrafraction patient motion. To limit interfraction 
patient motion and interfraction tumour motion, this group used CBCT. Senan et al. 
used 4DCT for assessing and incorporating intrafraction tumour motion, CBCT for 
interfraction tumour and interfraction patient motion and the Exactrac system 
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intrafraction patient motion. The Japanese trial was a combination of many different 
immobilization and verification techniques.  
The doses used in the three papers also differ, which may have resulted in the slightly 
different toxicity outcomes. Timmerman et al. used 60-66Gy in 3 fractions, Senan et al. 
used a variety of fractionation regimens depending on the likelihood of toxicity, but 
both of these papers had a biological effective dose of up to 180Gy. The Japanese 
paper used a wide range of doses (range 57Gy - 180 Gy) and found that there was a 
statistically significant outcome if doses were >100 Gy. As there is now significant 
literature on the tolerance and quality of life after a biological effective dose of around 
180 Gy, this is usually what is used.  
Despite different techniques, the outcomes in the three trials are similar. Timmerman 
recently published extended follow up of his prospective Phase II trial quoting 2-year 
local control rates of 95%. The Senan group had a median follow up of 12 months and 
reported a local control rate of 93%. Onishi et al. had a median follow up of 24 months 
and showed a local control rate of 92.9%, 3-year lung cancer specific survival was 
88.4%. These outcome data are so good that there is a division in the radiation oncology 
community as to the next step. Some feel a Phase III randomised controlled trial of 
SBRT versus standard conformal radiotherapy is required and there is such a trial 
ongoing in Scandinavia, a similar trial from the Netherlands had to close due to poor 
accrual therefore it is unknown whether a trial of this nature will ever be successful. 
The other group feel the outcomes are comparable to those of surgery (outcomes of 
which are discussed in section 1.1.4) and Phase III randomised controlled trials of 
surgical resection versus SBRT are underway. Unfortunately the UK is lagging behind 
and certain centres have only just begun to implement SBRT into clinical practice.  
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1.4 Aims 
 
The hypothesis of this work was whether IGRT could be safely implemented for clinical 
use in a busy oncology centre. The Beatson, West of Scotland Cancer Centre, as many 
centres in the UK are extremely busy and any development must be safe, of proven 
clinical benefit and optimised to minimise additional resource. The projects undertaken 
were to ensure that the implementation of IGRT fulfilled these criteria. It was also 
important to address issues that were of use to the wider wider international 
radiotherapy community’s knowledge on IGRT in lung cancer.  
The calculation of set-up errors at our centre, to facilitate all further investigation into 
IGRT is obviously the first step in this thesis. This was required to ensure the safety of 
any IGRT process. With a view to implementing 4DCT, there was an obvious paucity of 
papers discussing how to define the target in node-positive patients, so further work 
was required prior to use of 4DCT to ensure the method suggested of using the MIP 
image was safe. MV-cine offer a simple, method of verification, without additional 
radiation exposure, that is available to on all modern LinAcs and therefore of interest 
due to the safety and lack of impact on resource. Investigation into whether these fulfil 
a role in radiotherapy verification is of interest. AMTD is a topic that many centres 
around the UK have discussed implementing, and the VUMC have already implemented 
however, further studies are required to assess the robustness of this technique.   
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2. THE CALCULATION OF AN SITE SPECIFIC MARGIN FROM INTERNAL TARGET VOLUME 
(ITV) TO PLANNED TARGET VOLUME (PTV) 
 
 
2.1 Introduction 
 
Currently in The Beatson West of Scotland Cancer Centre, as discussed in the 
introduction during 3-D CT based radiotherapy of lung cancer, a combined margin from 
GTV to PTV of 15mm anteriorly, posteriorly and in both directions laterally and 20mm 
superiorly and inferiorly is used. This margin is to encompass microscopic disease, a 
population based margin for intra-fraction respiration induced tumour motion, and the 
set-up margin from ITV to PTV as suggested by the ICRU guidelines [19,20]. However, 
only the GTV to CTV margin for microscopic disease is quantified. Although Giraud et 
al. quantified a microscopic margin of 6-8mm, when this is used in combination with 
other margins in clinical practise, 5mm is most commonly used. As discussed in section 
1.2.5, margins are not added linearly and it is up to the local centre how to combine 
the different margins. The general consensus worldwide is that when in combination 
with other margins, this margin should be 5mm. Neither the population based margin 
for intra-fraction respiratory induced tumour motion nor the set-up margin from ITV to 
PTV have ever been quantified in our centre. As a result, the amount of the combined 
margin that is allocated to each specific margin is unknown. 
 
There are three main reasons why calculating the ITV to PTV set-up error is vital, 
especially in any study of IGRT. 
1) Even without the study of IGRT, set-up errors vary from centre to centre. The 
verification techniques differ in the types of images used, how they are acquired 
and analysed, and the acceptance thresholds. . As a result set-up errors should be 
calculated on a centre-specific basis so that they are accurate and they are neither 
too small resulting in geographical miss, nor too big resulting in unnecessary 
irradiation of normal tissue.  
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2) As discussed above, one of the imaging technologies used in IGRT is 4DCT for  
planning, which allows the intrafraction respiration-induced tumour motion to be 
visualised so that the margin for this motion can be individualised. In 4DCT scans, 
the volumes delineated begin with GITV, which is grown to CITV for microscopic 
disease followed by a further margin for set-up error to create the PTV, as 
discussed in section 1.3.2. If the set-up margin from CITV to PTV is currently 
unknown, this needs to be calculated so that once a GITV has been delineated on a 
4DCT scan, and the 5mm has been added for microscopic disease, an accurate set-
up margin can be added to create the PTV.  
3) As a result of different verification protocols and the corrections applied, the 
set-up error varies between centres. Online imaging with CBCT and kV imaging can 
be used to minimise the set-up error so that target coverage is improved and 
margins can potentially be reduced to spare more normal tissue. In order to 
implement CBCT and kV imaging, and to confirm these new imaging technologies 
are reducing the set-up errors from our current practice, it is necessary to estimate 
a baseline set-up error using our current off-line verification technique. 
 
There are two margin recipes that are used widely. McKenzie et al. wrote extensively 
in a British Institute of Radiology publication on how to calculate the standard 
deviation of the systematic and random set up errors from iso-images. He derived an 
equation to calculate the set-up margin [23]. Van Herk et al. also published a margin 
recipe [22]. The McKenzie paper was used to calculated the standard deviation of the 
systematic and random errors in our department, and then used both the McKenzie and 
van Herk margin equations to calculate our site specific CITV to PTV margin. 
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2.2 Method 
 
• McKenzie Publication 
 
McKenzie discusses two aspects of the margin he has published. The first stage called 
the “treatment preparation” is to determine a volume large enough to contain the CTV 
in the majority of cases so that the defined volume will encompass the mean position in 
90% of cases. This stage of delineation is primarily concerned with the intra-fraction 
tumour motion as a result of respiration. However, as 4DCT enables the GITV to be 
individually visualised and delineated it is not necessary to include this potential error 
in our margin and hence, this stage is not required. We therefore concentrated on the 
second stage of defining treatment margins which is to calculate an uncertainty of 
position as a result of set-up errors only. As there can be movement in three 
dimensions, the calculation has to be performed separately for lateral movement, 
superior/inferior movement, and anterior/posterior motion. 
 
The McKenzie et al. equation to calculate CTV to PTV margin: 
 
2.5 Σ + a + b + β(σ – σp) 
 
 
Symbol 
 
Explanation 
Σ Standard deviation of the systematic error. 
a The photon beam algorithm error. 
b Motion of the target caused by breathing. 
β 
This depends upon the detailed beam configuration and is given in the 
publication. 
σ Standard deviation of the random error. 
σp The unblurred photon beam penumbra width. 
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How each parameter was calculated will be discussed in turn. 
 
1) The Standard Deviation of the Systematic Error (Σ) 
 
Σ represents the systematic errors that are incorporated into the margin in a Gaussian 
fashion. A number of potential systematic errors make up Σ and the value is calculated 
by adding these together in a quadratic fashion. Of these errors, the most significant 
one is the standard deviation of the systematic set-up error. The majority of the other 
errors mentioned such as a phantom transfer error, treatment planning system error 
and LinAC geometry error, are so insignificant that in the face of larger errors being 
added in a quadratic nature, they would have had no effect on the final value and were 
therefore not calculated. The only other systematic error that has the potential to be 
large and may have some effect on the final value is the interclinician variation error 
which will be discussed in some detail later.  
 
To calculate the standard deviation of the systematic set-up error, a research 
radiographer reviewed pairs of AP and lateral MV orthogonal iso-images of 100 patients 
retrospectively. Each patient had between 2 and 10 iso-images each taken on different 
fractions for off-line verification. There were 412 images analysed in total. Reference 
landmarks were delineated on the DRR created from the planning CT and then on the 
iso-images. These reference landmarks were highlighted on the iso-images and 
compared to the same landmarks on the DRR produced at planning. The iso-image was 
shifted to match the DRR image as closely as possible. It is important to use reference 
landmarks that are immobile, or do not exhibit any interfraction patient motion, such 
as the paraspinal line, clavicle, trachea, thoracic wall and apex of lung [109,110]. The 
deviation from the iso-image position to the DRR position in all three directions, 
superior/inferior, laterally and anterior/posteriorly was noted. The above analysis was 
performed by the research radiographer, the accumulation of this data and all further 
analysis was performed by myself. All the deviation data was recorded in Microsoft 
Office XL Professional 2007, one page for each direction. To calculate the standard 
deviation of the systematic set up error, the following equation was used: 
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Σ set-up =  √ [       P         ∑ np (mp – m overall)2 ] 
         N (P – 1) 
 
 
 
Symbol 
 
Explanation 
Σ set-up 
 
Standard deviation of the systematic treatment set-up error for all 
patients P in a given direction. 
P 
 
Total number of patients for which images were acquired. 
N 
 
Total number of images in study 
np 
 
Number of images taken for patient p. 
mp 
 
Mean set up deviation for patient P. 
moverall 
 
Overall mean population error. This is the mean systematic set-up error. 
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• The anterior / posterior standard deviation of systematic set-up error was 
calculated as:  3.0mm 
 
• The superior / inferior standard deviation of systematic set-up error was 
calculated as:  3.0mm 
 
• The lateral standard deviation of systematic set-up error was calculated as: 
   2.9mm 
 
The inter-clinician variation, which is the difference between GTVs drawn by clinicians, 
has been calculated in a number of papers and the figures vary widely [39,40]. There 
was an attempt to ask clinicians at our own centre to delineate the same patients so to 
enable site-specific inter-clinician variation to be calculated, but due to time 
constraints on our clinicians and the volume of additional delineation required to 
achieve any sort of meaningful figure, this was not possible. It became apparent after a 
few delineations that in lung cancer, the large inter-clinician errors do not occur as a 
result of discrepancies at the edges around the same agreed high density area or lymph 
node, but in deciding whether or not to include a lymph node in the volume or a blood 
vessel in the volume, or an area of opacified lung in the volume. This variation cannot 
easily quantified and added to a margin, as clinicians can identify gross tumour that lies 
centimetres away from the primary tumour in any direction and incorporating this 
would likely involve large margins in some directions that bear no relevance to the 
majority of patients. In order to assess whether this made a significant difference to 
the margin we calculated a margin with and without incorporating the error to enable 
us to decide whether it was feasible to incorporate this into the margin recipe. 
To identify a figure for interclinician variation, as it proved impossible to calculate one 
at our centre, we conducted a literature search for an appropriate value. A literature 
search for “interclinician variation” and “delineation variation” was undertaken on 
“PubMed” and “ScienceDirect” for any papers regarding interclinician discrepancies 
within the last ten years. Steenbakkers et al. calculated the standard deviation of the 
interclinician discrepancies [24]. This paper was chosen as it had the largest number of 
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patients and radiation oncologists and it also had a wide range of tumour positions and 
stages. Eleven radiation oncologists were asked to delineate 22 patients. The radiation 
oncologists were given all the clinical information, all available pathology and the 
diagnostic scans and asked to delineate the GTV.  The observer variation was computed 
in three dimensions by measuring the distance between the median GTV surface and 
each individual GTV. The inter-clinician discrepancy error, as described by 
Steenbakkers et al. was 4.2mm. This was with the use of PET/CT in planning as most 
patients are planned with the assistance of PET/CT scans at The Beatson, West of 
Scotland Cancer Centre.  
The margins in all three directions were initially calculated without the inter-clinician 
error for the reasons given above. In this equation, the sole error to be incorporated 
into Σ was the standard deviation of the systematic set-up error. However in addition, 
the figure of 4.2mm was then incorporated in a further calculation to see whether 
incorporating this error would make a large difference to the final set up error. 
 
 
2) Treatment planning system (TPS) beam algorithm error (a) 
 
This is an error incorporated to allow for any error in the planning algorithm 
calculation. This would result in a systematic under dosing of the target by the linear 
accelerator beams therefore the margin for this error is added linearly. The 90% dose 
level is used to determine the correction. The TPS beam algorithm error when 
calculated on different systems falls between -2 to 2mm. 2mm was used in the 
equation as it is the maximum error that could occur and using 2mm would mean all 
potential error would be included in the margin. 
 
 
 
 
3) Breathing positional error (b) 
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This is the amplitude of motion of the CTV caused by respiratory induced motion. As 
discussed above, we plan to address this error by using 4DCT where the GITV already 
encompasses an individualised margin for respiration induced tumour motion and 
hysteresis. We therefore used 0mm in the equation as this is already incorporated in 
the volume.  
 
 
4) Planning Parameter (β) 
 
The value of β depends on the different beam combinations. A table providing the 
different values for the planning parameter error is present in the document. The value 
chosen depends on the number of beams in use and gives different values for the error 
in transverse and superior / inferior directions.  
• For a 3 field plan, as is routinely used for radical lung treatments, the value for 
(β) in the superior / inferior direction is 1.64. 
• For a 3 field plan, the value for (β) in a transverse plane with beams not 
parallel and opposed is 1.04. 
 
 
5) Treatment execution errors (σ) 
 
The main two parameters that need to be combined in quadrature to give σ are the 
standard deviation of random set-up error and the penumbra width (σp) 
 
To calculate the standard deviation of random set-up error, the same iso-images and 
deviations noted in the calculation of the systematic set-up error were used with the 
following equation to calculate the standard deviation of the random set-up error.  
 
The McKenzie et al. equation for the standard deviation of the random set-up error is: 
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σ set-up =  √ [      1        ∑  σ 2 inter ( np - 1) ] 
   N – P 
 
Symbol 
 
Explanation 
σ set-up 
Standard deviation of the random treatment set-up error for all 
patients P in a given direction. 
P Total number of patients for which images were acquired. 
N Total number of images in study 
np Number of images taken for patient p. 
σ2inter 
Standard deviation of the inter-fractional random treatment set-up 
error for patient p in a given direction. 
 
• The anterior / posterior standard deviation of the random set-up error was 
calculated as:  0.8mm 
 
• The superior / inferior standard deviation of the random set-up error was 
calculated as:  3.6mm 
 
• The lateral standard deviation of the random set-up error was calculated as: 
  2.7mm 
 
 
 
 
 
 
6) Photon Penumbra Width (σp) 
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The penumbra is the area on the edge of the beam that can receive radiation from 
some parts of the source but not from the whole source. This depends on the diameter 
of the source, the source-skin distance and the collimated length. This was calculated 
by the on site Dosimetry Physicists using appropriate parameters for lung cancer plans. 
The penumbra width for a 10cm x 10cm field at 5cm depth was calculated as 8.5mm. 
  
 
• Van Herk Publication 
 
In order to validate the margin given by the McKenzie equation, a further margin was 
calculated using the van Herk equation: 
 
2.5 ∑ + 0.7 σ 
 
 
 
 
 
 
 
 
 
 
 
 
2.3 Results 
 
• McKenzie Equation 
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The results of the calculations using the McKenzie equation to calculate the CITV to 
PTV margin without adding the interclinician variation are:  
  
In the anterior/posterior position: 
 
Margin =  2.5 Σ + a + b + β(σ – σp)  
Margin =  (2.5 x 3.0) + 2 + 0 + 1.04 [√(8.52 + 0.82) – 8.5] 
Margin =  9.5mm 
 
 
In the superior/inferior position: 
 
Margin =  2.5 Σ + a + b + β(σ – σp) 
Margin =  (2.5 x 3.0) + 2 + 0 + 1.64 [√(8.52 + 3.62) – 8.5] 
Margin =  10.7mm 
 
 
In the each lateral direction: 
 
Margin =  2.5 Σ + a + b + β(σ – σp) 
Margin =  (2.5 x 2.9) + 2 + 0 + 1.04 [√(8.52 + 2.72) – 8.5] 
Margin =  9.7mm 
 
 
The same McKenzie equation was performed but this time incorporating 4.2mm as the 
value for inter-clinician variability as discussed above. The results of the further 
calculation are: 
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In the superior/inferior position: 
 
Margin =  2.5 Σ + a + b + β(σ – σp) 
Margin =  (2.5 x √3.02+4.22) + 2 + 0 + 1.64 [√(8.52 + 3.62) – 8.5] 
Margin =  16.1mm 
 
• Van Herk Equation 
 
The results of the calculations using the van Herk equation to calculate the CITV to PTV 
margin are: 
 
In the anterior/posterior position: 
 
Margin = 2.5 Σ + 0.7 σ 
Margin = 8.1mm 
 
In the superior/inferior position: 
 
Margin = 2.5 Σ + 0.7 σ 
Margin = 10.0mm 
 
In the each lateral direction: 
 
Margin = 2.5 Σ + 0.7 σ 
Margin = 9.1mm 
2.4 Discussion 
 
These two equations are different and either can be used taking into account certain 
caveats. The Van Herk equation was calculated so that 90% of patients receive at least 
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95% to the CTV. In the McKenzie equation, the objective was to have a large enough 
margin between the edge of the incident radiation beam and the CITV that over the 
course of the fractionated schedule the accumulated dose is >95%. Both equations 
imagined the penumbra to be blurred. This blurring occurs due to the motion between 
the target and the beam, both due to day-to-day differences over the treatment course 
and target motion during a fraction. As a result both equations are only applicable to 
fractionated treatments and cannot be used in hypofractionated treatments such as 
SBRT. The main problem with the Van Herk equation is that it is calculated presuming 
the tumour is a perfect sphere, and treatment is entirely conformal. This results in a 
“fringe dose” where there is a background dose because of the penumbras of multiple 
other beams. McKenzie et al. address this by removing this fringe dose so that it can be 
applied with less beams and less conformal treatment hence calculation for an onsite 
penumbra. Despite these slight differences, it is reassuring to note the similar results 
obtained in both calculations.  
 
The addition of the inter-clinician error resulted in a significant increase the margins. 
However, whether or not to use this larger margin has to be considered. One has to ask 
whether the incorporation of inter-clinician value will increase the likelihood of 
covering 90% of patients with a minimum dose of 95% as the two margins are designed 
to do. The inter-clinician variation in lung cancer tends to be whether or not to include 
a structure, rather than a delineation line falling a few millimetres symmetrically round 
an agreed structure. To incorporate this error would increase the margin by around 
6mm however as different clinicians identify different areas of gross tumour that are 
usually more than 6mm from the primary GTV this addition is unlikely to improve 
tumour coverage. A true interclinician variation would be the estimate of the error 
drawing lines around agreed structures, these would be very small and added together 
in quadrature, would likely not influence the margin. We therefore plan to use the 
margin calculated without the incorporation of an inter-clinician variation error.  
This work highlighted the need to improve interclinician variation within the 
department. Since this work was carried out there has been a planning meeting 
introduced where volumes are assessed by all clinicians. There is a radiologist and 
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nuclear medicine physician present to assist with the interpretation of images. There 
are also proposals being put together to import the PET images into the delineation 
system to reduce this further.  
 
As most centres have improved their set up with online imaging, or use shrinking action 
protocol or the no-action level protocol, it is difficult to find papers using a similar off-
line verification technique from recent years. However in 2001, Hurkmans et al. 
published a review of set up errors in the thoracic region. These were with different 
immobilisation techniques but prior to the advent of online imaging. The standard 
deviation of the systematic error ranged from 1.8mm to 5.1mm and the SD of the 
random error ranged between 2.2mm and 5.4mm. Our set up errors are on the better 
end of these figures, probably as a result of improved immobilisation and the vague, 
subjective off-line review technique that we use [111]. 
 
As most of the values calculated were 10mm +/- 2mm, and the fact it is easier in a 
large institution to have one value for all directions, consequently a margin of 10mm is 
recommended for set-up margin for further investigation.  
 
 
 
 
 
 
 
 
 
3. THE USE OF THE MAXIMUM INTENSITY PROJECTION (MIP) FOR TARGET OUTLINING IN 
4DCT RADIOTHERAPY PLANNING. 
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3.1 Introduction 
 
As discussed in the introduction, the intra-fraction movement of lung tumours for 
radical radiotherapy is currently encompassed within the margin between the CTV and 
the ITV. With the traditional method of Helical CT scans for conformal planning, the 
intra-fraction movement, due primarily to respiration, cannot be quantified accurately, 
therefore a standard “population-based margin” is applied. The margin applied is 
crudely assessed for each individual patient in turn using fluoroscopy at the 
radiotherapy simulator and altered only if the tumour is obviously moving out with the 
PTV.  
 
The system to create 4DCT’s used in both centres where this work was carried out is 
discussed in detail in section 1.3.2 (page 20). Figure 3-1 illustrates this further. As is 
discussed, there are a few different images created; the phase bins of the different 
respiratory cycles, the MIP, the MinIP and the Ave-IP as seen in Figure 1-4.  
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Figure 3-1 An illustration of how the 4DCT scan is captured. The respiratory cycle is the 
motion of an external surrogate on the xiphisternum. During each respiratory cycle, 
20mm of chest is imaged 10 consecutive times. Each image captured, taken at a 
different phase of respiration is demonstrated by the image-set names 0%, 10%, 20%.. 
to ..90%. During sorting of the images, all the images corresponding to a specific phase 
of the respiratory cycle (eg. maximum inspiration or 0%) are put on top of one another, 
to create an image-set of maximum inspiration that is in fact the combination of a 
large number of images taken over a large number of respiratory cycles. Ten different 
image-sets are created in this way representing different phases of the respiratory 
cycle. 
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There have been various methods of creating a GITV or CITV from a 4DCT dataset 
reported. Whether it is a GITV or CITV depends on whether the clinician is delineating 
the gross tumour or the gross tumour with a margin for microscopic disease on the 
4DCT. The first, most robust, but time consuming method, is to create a GTV or CTV on 
each of the 10 image-sets representing 10 phases of the respiratory cycle from the 
4DCT dataset and combine these to create the GITV or CITV.  
 
As radiotherapy centres implement 4DCT into planning, a limiting factor to clinical use 
is the time taken to delineate 10 scans for each patient. An alternative delineating 
method might be to use the MIP image set to create the GITV or CITV. One of the first 
questions that will be asked by centres implementing 4DCT is whether the GITV created 
using the MIP image, accurately represents the GITV or CITV. The advantage of this 
method is that once the MIP image set is produced, it comprises just one CT scan that 
should take no longer to volume than the current 3D helical scans. In a stretched 
radiotherapy centre such as the Beatson, this would obviously the ideal, we therefore 
elected to investigate the safety of this method further. 
 
There is conflicting evidence in the literature regarding the use of MIPs for delineation. 
For Stage I lung tumours, Underberg et al. compared GITV_MIP (a GITV created using 
the MIP image) with GITV_10phase (a GITV created by making a composite of GTVs 
delineated on each of the 10 bins in turn) which is the gold standard method of 
delineation, in 12 patients [112]. They concluded that contouring of MIP scans was a 
reliable and fast clinical tool for generating GITVs. In the discussion, concerns were 
raised regarding the use of MIP in more advanced tumours. For node positive tumours, 
Ezhil et al. compared GITV_MIP to GITV_10phase in 27 patients with Stage I – III NSCLC 
[113]. They concluded that for all stages of disease, the GITV_MIP was significantly 
smaller in volume than the GITV_10phase.  
 
As MIP is the most efficient method reported, we felt there was a lack of a 
comprehensive study to ascertain whether it is safe to delineate using the MIP, 
especially in node positive patients. Although the Ezhil et al. suggested the GITV_MIP is 
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smaller than the true GITV seen with GITV_10phase, this required additional 
confirmation. Consequently, it was elected to investigate whether the MIP image can 
be used in node-positive patients who constitute the majority of patients receiving 
radical radiotherapy.   
 
 
3.2 Methods 
 
CT image acquisition 
All patients were routinely immobilised using a Sinmed Posirest Thoracic Board (Sinmed 
BV, The Netherlands) and a knee support prior to scanning on a GE Lightspeed RT 16 
Multi-slice CT scanner (GE Healthcare, UK). Fifty millilitres of Omnipaque 300 
intravenous contrast was administered by Stellant Contrast Injector. A helical scan was 
acquired followed immediately by a 4DCT taking a total <3minutes. Patients were 
asked to breathe freely throughout and scans covered the whole chest cavity.  
 
4DCT scanning was performed using the Varian Real-Time Positioning Management 
System as described in detail in section 1.3.2 (page 20). Scanning parameters were set 
at 120 kV, 20mA with a slice thickness of 2.5mm. A block containing infrared-reflecting 
markers was placed on the patients’ xiphisternum to monitor respiration. The motion of 
the block was captured by a camera fixed to the end of the treatment couch and a 
respiratory signal was displayed in the control room. For each patient the respiratory 
cycle was assessed. The cine-duration, which is the period of time for which the couch 
is static and images are acquired, was set as the mean respiratory cycle length for that 
patient plus 0.5 seconds. The X-ray tube rotation was set to 1/10th of the respiratory 
cycle length. In each static couch position, 8 contiguous slices of 2.5mm were acquired. 
The couch position was indexed by 20mm and the process repeated. Mean respiratory 
cycle lengths ranged from 2.9s to 7.9s. The helical scan acquisition time was about 18 
seconds and the 4DCT acquisition time was about 90 seconds. 
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The 4DCT dataset was transferred to an Advantage 4D workstation (GE Healthcare, UK) 
where a software package was used to create 10 different scan sets relating to 10 
sequential phases of the respiratory cycle, using the amplitude of the respiratory trace. 
These are labelled 0%, 10%, …. ,  90%. The 4D software was also used to create a scan 
MIP from the raw data as described in section 1.3.2. 
 
Patient Selection 
This was a retrospective analysis for patients who had undergone both Helical and 4DCT 
for their radical radiotherapy planning. Fourteen consecutive patients, presenting to 
one consultant with radically treatable NSCLC, over a 4 month period, were studied.  
 
Generating Target Volumes 
The target outlining in all 14 patients was completed by the author. Helical scans were 
transferred directly from the scanner to the Varian Eclipse Treatment Planning System, 
software version 6.5 (Varian Medical Systems, Palo Alto, CA). The 4DCT was sent 
initially to ADW and once the creation of the respiratory bins had occurred, they were 
also transferred to the Varian Eclipse Treatment Planning System. The scans were 
viewed and outlined in the Beatson’s standard mediastinal and lung window settings (-
130HU to 200HU and -1000HU to -200HU, respectively). The CTV’s of the primary 
tumour included all gross disease, with a margin added manually of approximately 
3mm. Lymph nodes were included if they measured >1cm in diameter and were also 
given a margin of around 2-3mm to account for microscopic disease.  
On the MIP image set, the gross tumour was delineated with a margin of ~3mm for 
microscopic disease. This created a CITV and was labelled CITV_MIP. 
To create the composite volume from all 10 phases (CITV_10phase), each of the 10 
phase image sets was contoured individually to create 10 CTVs. The images were all 
registered to a reference image, and CTVs from each phase were copied onto the 
reference image. Algebraic operators were used to create the CITV_10phase.  
The MIP image was also registered with the reference image and the CITV_MIP was 
copied across so that it could be compared directly with the CITV_10phase. 
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Analysis of Target Volumes 
The volumes of the two CITVs were compared by calculating the ratio between them. 
The regions on the scan where the volumes most differed were noted. Algebraic 
operators were used on the Varian Eclipse system to determine the volume of tissue 
enclosed by the CITV_10phase but not by CITV_MIP and, likewise, the volume of tissue 
enclosed by the CITV_MIP but not the CITV_10phase. The centre of mass co-ordinates 
(COM co-ordinates) of both volumes were recorded and compared. 
 
Statistical Analysis 
Wilcoxon signed-rank test, calculated on SPSS 15.0 for Windows, was used to compare 
volumes. A p≤0.05 was considered statistically significant. 
 
 
 
3.3 Results 
 
Tumour stages varied from Stage IB to Stage IIIB (Table 3-1). 
 
Comparison of CITV_10phase to CITV_MIP 
These results are presented in Table 3-2. In all patients the CITV_10phase was equal to 
or larger than the CITV_MIP. The mean ratio (+ S.D.) of CITV_10phase /CITV_MIP was 
1.23 ± 0.17. The 95% confidence interval was between 1.13 and 1.32. The Wilcoxon 
Signed-Rank test showed there was a statistically significant difference between the 
two volumes (p= 0.001).  
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Table 3-1. Tumour Characteristics 
 
 
 
Patient 
 
TNM stage 
 
Stage 
 
Position 
    
Patient A T2 N0 Stage IB LLL 
Patient B T2 N0 Stage IB LUL  
Patient C T2 N2 Stage IIIA RML. Partial collapse of RML 
Patient D T4 N0 Stage IIIB Rt pancoast tumour 
Patient E T4 N2 Stage IIIB Rt pancoast tumour 
Patient F T2 N1 Stage IIB RUL. Collapsed RUL. 
Patient G T2 N2 Stage IIIA RML. Adjacent to hilum 
Patient H T4 N2 Stage IIIB LLL. Infiltrating pulmonary artery 
Patient I T1 N2 Stage IIIA LUL. Adjacent to hilum 
Patient J T2 N2 Stage IIIA RLL. Adherent to diaphram 
Patient K T2 N1 Stage IIB RML. Adjacent to hilum 
Patient L T0 N2 Stage IIIA Mediastinal recurrence following lobectomy 
Patient M T2 N1 Stage IIB RUL  
Patient N T2 N1 Stage IIB RML. Adjacent to hilum 
 
LUL – left upper lobe. LLL – left lower lobe. RUL – right upper lobe. RML – right mid 
lobe. RLL – right lower lobe. 
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Table 3-2. Comparison of CITV_10phase to CITV_MIP 
 
 
 
CITV_10phase 
(cm3) 
CITV_MIP 
(cm3) 
 
Difference in 
Volumes 
(cm3) 
CITV_10phase/ 
CITV_MIP 
 
Patient A 
 
37.0 
 
36.8 
 
0.2 
 
1.01 
Patient B 26.0 24.9 1.1 1.04 
Patient C 140.1 116.2 23.9 1.21 
Patient D 96.2 80.4 15.8 1.20 
Patient E 67.2 52.2 15.0 1.29 
Patient F 120.1 94.3 25.8 1.27 
Patient G 111.4 91.5 19.9 1.22 
Patient H 99.4 87.5 11.9 1.14 
Patient I 112.5 87.3 25.2 1.29 
Patient J 215.8 138.9 76.9 1.55 
Patient K 71.2 63.2 8.0 1.13 
Patient L 40.4 26.2 14.2 1.54 
Patient M 51.7 39.0 12.7 1.33 
Patient N 37.2 37.0 0.2 1.01 
     
Mean +/- S.D    1.23 +/-0.17 
Median    1.22 
P-value    0.001 
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The median percentage of CITV_10phase, or potentially tumour tissue, which was not 
covered by the CITV_MIP, was 19.0% (range 5.5% – 35.4%) (Table 3-3). There was good 
agreement in delineation in areas where the higher density tumour adjoined lower 
density lung tissue. However, significant differences in delineation occurred where 
tumour adjoined the mediastinum or diaphragm i.e. where the tissue has a similar 
density to tumour. This is demonstrated in Figure 3-2. The median percentage of 
CITV_MIP that was not covered by CITV_10phase was 2.3% (range 0.4% - 9.8%) (Table 3-
4). These areas were randomly distributed around the circumference of the volume and 
relate to very small displacements of the contour lines. 
 
In the two patients with Stage I disease (Patients A and B), the CITV_MIP and 
CITV_10phase volumes were very similar with the ratios of 1.01 and 1.04 (Table 3-2). 
Only 6.8% and 5.5% of CITV_10phase was not enclosed by MIP (Table 3-3). These 
tumours were entirely surrounded by low density lung tissue and contour lines were 
again displaced by very small distances.  
 
Comparison of COM co-ordinates 
The COM co-ordinates and calculated displacement of centres are shown in Table 3-5. 
In the superior/inferior axis, medio-lateral axis and anterior/posterior axis the mean 
distance between co-ordinates was 0.15cm, 0.13cm and 0.07cm respectively. The mean 
(+ S.D.) displacement of the centres was calculated as 0.34cm (±0.31). There were 5 
patients with a displacement of COM of ≥0.4cm. This level of displacement would cause 
a significant systematic error affecting ITV to PTV margin. 
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Table 3-3. The percentage volume covered by CITV_10phase that remained uncovered 
by CITV_MIP. 
 
 
 
 
 
 
 
Volume of CITV_10phase 
not encompassed by 
ITV_MIP (cm3) 
Volume of CITV_10phase 
(cm3) 
% of CITV_10phase not 
encompassed by ITV_MIP 
 
Patient A 
 
2.5 
 
37.0 
 
6.8 
Patient B 1.4 26.0 5.5 
Patient C 30.9 140.1 22.1 
Patient D 11.6 96.2 12.1 
Patient E 15.0 67.2 22.3 
Patient F 23.1 120.1 19.2 
Patient G 17.2 111.4 15.4 
Patient H 18.0 99.4 18.1 
Patient I 25.1 112.5 22.3 
Patient J 76.4 215.8 35.4 
Patient K 13.4 71.2 18.8 
Patient L 13.0 40.4 32.2 
Patient M 11.4 51.7 22.1 
Patient N 2.5 37.2 6.6 
    
Mean +/- S.D   18.5 +/- 8.5 
Median   19.0 
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Table 3-4. The percentage volume covered by CITV_MIP that is uncovered by 
CITV_10phase. 
 
 
 
 
 
 
 
 
Volume of CITV_MIP not 
encompassed by 
CITV_10phase (cm3) 
Volume of CITV_MIP (cm3) 
 
% of CITV_MIP not 
encompassed by 
CITV_10phase 
 
Patient A 
 
1.3 
 
36.8 
 
3.6 
Patient B 0.2 24.9 0.9 
Patient C 2.0 116.2 1.7 
Patient D 0.3 80.4 0.4 
Patient E 2.5 52.2 4.9 
Patient F 0.5 94.3 0.6 
Patient G 0.5 91.5 0.5 
Patient H 7.5 87.5 8.6 
Patient I 1.9 87.3 2.2 
Patient J 3.5 138.9 2.6 
Patient K 6.2 63.2 9.8 
Patient L 0.6 26.2 2.4 
Patient M 0.7 39.0 1.7 
Patient N 2.7 37.0 7.4 
    
Mean +/- S.D   3.4 +/- 3.0 
Median   2.3 
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Table 3-5. The COM Co-ordinates in the two different volumes (cm).  
x= left/right axis, y= anterior/posterior axis, z= superior/inferior axis. 
 
 
 CITV_10phase CITV_MIP 
 
Distance between 
centres 
 x,  y,  z x,  y,  z (cm) 
 
Patient A 
 
3.5,1.5,1.3 
 
3.9, 1.8, 1.3 
 
0.45 
Patient B 6.9, 8.1, -7.8 6.9, 8.1, -7.9 0.06 
Patient C -6.0,-4.2, 1.0 -6.2, -4.2, 1.0 0.23 
Patient D -6.7, 5.0, 11.7 -6.7, 5.0, 11.8 0.10 
Patient E -5.0, 1.5, 7.6 -5.5, 1.7, 8.5 1.05 
Patient F -3.7, -0.2, 6.2 -3.7, 0.0, 6.3 0.11 
Patient G -2.7, -0.1, 1.0 -2.7, 0.0, 1.1 0.13 
Patient H 8.6, 5.5, -3.3 8.6, 5.5, -3.3 0.04 
Patient I 5.2, 0.5, -0.1 5.5, 0.4, 0.2 0.45 
Patient J -7.0, -0.3, -2.2 -6.3, -0.1, -1.6 0.96 
Patient K -8.3, 3.0, 0.8 -8.7, 3.3, 1.0 0.53 
Patient L -0.9, -1.4, 4.8 -0.9, -1.5, 4.6 0.21 
Patient M -4.6, 1.5, 7.0 -4.8, 1.7, 7.0 0.25 
Patient N -5.8, -0.4, -3.6 -5.7, -0.4, -3.5 0.16 
    
Mean ± S.D.   0.34 ± 0.31 
Median   0.22 
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Figure 3-3. A coronal view of a planning 4DCT with CITV’s created using different 
methods. The CITV_10phase is in cyan and the CITV_MIP in red. This demonstrates the 
high density areas missed by the CITV_MIP. 
 
 
- 75 - 
3.4 Discussion 
 
This study suggests that CITV_MIP cannot be used for accurate delineation of Stage II-III 
tumours as there are significant volumes of tumour tissue, identified by the 
CITV_10phase, that are not encompassed by the CITV_MIP. In contrast, CITV_MIP could 
be used for Stage I tumours, but this is based on data from only two patients.  
 
Although we have only limited data, and hence statistical findings may not be robust, 
18.5% of uncovered tumour is sufficient to raise concerns regarding this method. 
Allowing for the fact there were only two Stage I patients it is reassuring to find the 
results in these patients are in keeping with the findings of Underberg et al., that an 
ITV created using a MIP image is reliable. The concerns regarding locally advanced 
tumours mentioned in that discussion are corroborated by this study. Figure 3-3, used 
to illustrate the problems with MIP in locally advanced tumours, resembles the image 
used in the discussion of the Underberg paper. It is reassuring to note that even given 
the different observers and patient group, the conclusion remains the same. 
 
For those with experience in the use of 4DCT datasets, this is not a surprising finding. 
For most patients with Stage 1 NSCLC, a discrete tumour mass moves within much 
lower density lung tissue, allowing large differences in density providing obvious 
contour lines.  In patients with Stage II-III, the tumour mass will be adjacent, at least 
on some boundaries, to tissue of equal density, such as mediastinum, chest wall or 
diaphragm. A boundary between tumour and normal tissue may be clearly visible on 
any individual phase scan. On the MIP image, boundaries become blurred. There is a 
natural tendency towards presuming that tissue is ‘normal’ unless there is evidence 
otherwise and so the extent of disease tends to be underestimated on the MIP. It is 
possible that individual nodes may not be identified. This is an important point to 
highlight  to those beginning to use 4DCT, and a further discussion regarding alternative 
techniques will take place in more detail below.  
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The information from a diagnostic PET/CT was not available for this group of patients 
as it was not in routine use at the time of the planning scans. Although the use of 
PET/CT has a significant effect on inter-clinician variability, it should not impact on 
intra-clinician variability.  As there is no consensus on what level of SUV, or percentage 
of SUV, constitutes the tumour edge [39,114] PET/CT should be used for localisation 
purposes rather than delineation. Although it may have highlighted different nodal 
groups, hence increasing the CITVs, the intra-observer variation would be the same, 
hence generating the same outcome. 
 
The intra-observer variation goes some way to explain why in all cases the 
CITV_10phase is bigger than CITV_MIP. Intra-observer variations in PTV are reported to 
vary from 3.9cm3 to 95.8cm3 [115]. The algebraic method of adding volumes means that 
small drawing variations in different bins always forms a larger composite volume than 
if one volume alone was delineated as in CITV_MIP. As a result, small differences in 
CITVs such as 0.2cm3 or 1.1 cm3, as in the Stage I tumours, are likely due only to intra-
observer variation, rather than a difficulty in delineating the tumour. 
 
The creation of the CITV in the above manner with gross tumour and an additional 
margin of approximately 3mm, was adopted as a standard throughout all patients. For a 
more accurate addition of 5mm for microscopic disease, a GITV would be created with 
any of the below methods, and thereafter a margin of 5mm would be added to create 
the CITV. Although, for some, the method used in this study would not be standard 
delineation margins, what is important in the validity of the study is that the method 
used is consistent. As it is widely accepted that interclinician discrepancies remain 
high, there would be disagreement from some whichever method was used. The study 
remains valid as there was a consistent method used throughout all the delineation. 
The window levels were not according to EORTC guidelines however the same values 
were used throughout the study [116]. 
 
The major practical drawback to the use of ITV_10phase is the long operator time 
required. Delineation of 10 scans and creation of composite volumes takes on average 
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2.5 hours per patient and it is very desirable to reduce this time requirement. A 
number of alternative methods have been reported in the literature: 
1) Ezhil et.al. [108] described the creation of a structure labelled 
ITV_MIP_Modified. The ITV was delineated on the MIP image and this volume was 
superimposed onto each of the 10 phases in turn, where it was modified by only 
enlarging boundaries when appropriate. The ITV_MIP_Modified was in close 
agreement with ITV_10phase.  This could offer some time savings but remains a 
work intensive method.  
2) A number of studies created an ITV from a composite of the two scans with the 
tumour in the most superior and inferior position [51,117]. There are a number of 
concerns with this method. This does not take into account lateral or 
anterior/posterior motion of the tumour nor hysteresis. There is also evidence 
describing the lack of correlation between the primary tumour and lymph node 
movement [118,119]. When selecting the two scans for delineation it may be that 
the primary tumour and involved lymph nodes are at their craniocaudal extreme 
positions in different scans. Care must also be taken to review the 4DCT cinescan in 
all planes. The method can be used if careful review of the 4D window cinescan 
takes place, in all planes, noting any areas of significant movement in other 
directions. A margin could be added to the ITV to PTV margin for the additional 
movement and hysteresis that takes place as above. Unless used with care and 
experience, this technique could lead to geographical miss of disease. 
3) Wolthaus et.al. [120] reported a method for constructing a single CT scan from 
the 4D dataset which represents the tumour in its time-averaged position over the 
respiratory cycle (mid-ventilation scan). Whilst diaphragm movement could be used 
to quickly identify the mid-ventilation scan for Stage I tumours, for Stage II and III 
disease, delineation of all 10 phases was required, which is the time-consuming 
process we are trying to avoid.   
4) Bosmans et al. [121] described a method where the 4D cinescan is used to 
identify the scan where the tumour is in its central position and measure the 
motion of the tumour in all three orthogonal directions. After delineating a CTV on 
the half ventilation scan individual margins are added which are calculated using 
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the motion seen on the 4D cinescan. The volumes created in this method are 
comparable in the above paper.  
5) There are a number of other methods reported, using different imaging 
techniques for individualising margins including; slow CT [122], end-tidal breath-
hold CTs [123], composite of 2 different helical scans in maximal inhale and exhale 
[124] and breath-hold CT [125], however each of these have their drawbacks and as 
software and systems have moved on, the 4DCT dataset is now regarded as the gold 
standard. 
 
Although there is evidence that normal tissue irradiation is reduced and target 
localization improves with the use of individualized margins, it has to be noted there is 
a lack of clinical outcome data. As with the introduction of conformal radiotherapy, 
there is a general consensus within clinical circles that this constitutes an improvement 
from current techniques and a randomised control trial of 3D versus 4D planning scans 
may be difficult to recruit to on ethical grounds. Clinicians may feel 3D planning scan 
may constitute sub-optimal treatment. Hence a comparative study with outcome data 
and cost effectiveness data is unlikely to occur. 
 
For Stage II and III disease, with the planning system Eclipse Version 8.4 (Varian Medical 
Systems, Palo Alto, CA) that was in use during this study, using a 4DCT was not possible 
in routine patients due to time limitations involved in delineating ITV_MIP_Modified or 
ITV_10phase. This was primarily because the different image-sets were not 
automatically registered and volumes could not be combined easily between different 
image-sets. However since the study was completed, there has been an upgrade to 
Version 8.6. This version has undergone significant improvements to software and 
permits automatic matching and registration across multiple image sets where they are 
already DICOM matched i.e. they have been acquired in the same scan process. In 
addition, it allows blending of different image-sets so volumes delineated on one 
image-set can be manipulated while viewing a different image-set. Since the 
implementation of Version 8.6 we have put together a protocol for delineation of Stage 
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II-III NSCLC which is very similar to ITV_MIP_Modified which we know from the 
literature is comparable to the gold standard of delineating all 10 phases.  
The steps involved in delineation of a node positive tumour are as follows: 
1) The 4DCT movie, created by running all 10 respiratory phases together, is 
reviewed on Eclipse 8.6. 
2) The phases where the tumour is in the most extreme position in all 6 directions 
are identified. These often fall within the same 2 phases, representing expiration 
and inspiration but any number can be selected to ensure the extreme of position is 
captured. 
3) All the delineating is saved onto the Ave-IP, as this is the image-set that will be 
used for calculation, although this image-set is never visualised.  
4) The first image-set that was selected in step 2 is blended with Ave-IP, so that 
although the volume is being saved on Ave-IP, only the image-set selected is being 
seen, and a GITV is delineated.  
4) In turn, all the image-sets selected in step 2 are blended with Ave-IP and the 
GITV is enlarged with each image-set to encompass all gross tumour in all phases of 
the respiratory cycle. 
5) It is vital to remember that the GITV can only ever be enlarged. Although the 
gross tumour may not appear on the image-set being visualised, it has been present 
on a previously reviewed image-set as it has been included in the volume. 
 
In conclusion, in the meantime, in our centre, in Stage 1 disease, if the tumour does 
not sit adjacent to high density structures, we propose the use of target delineation on 
the MIP image-set target. In Stage II-III disease, we will use the method described 
above.  
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4. FEASIBILITY OF MV-CINE FOR VERIFICATION OF INTRAFRACTION TUMOUR MOTION.   
 
 
4.1 Introduction 
 
In the past, small irregularities in intrafraction tumour motion were not so clinically 
relevant due to the fact offline verification protocols resulted in large margins and 3D 
conformal therapy plans lacked the conformality of IMRT plans. However recent 
changes in radical radiotherapy in lung cancer have resulted in the assessment and 
verification of intrafraction respiration induced tumour motion becoming increasingly 
important: 
1) New, sophisticated planning and delivery techniques such as IMRT [126], 
stereotactic radiation therapy (SRT) [14] and Tomotherapy [127] can produce 
increasingly conformal treatment plans.  
2) It is also known that these technologies are labour-intensive and can lead an 
increase in treatment times [128] which in turn increases the risk of intrafraction 
shifts in tumour position [68].  
3) Due to the complexities of these delivery techniques concerns have been raised 
that therapy may be more error-prone [129].  
 
The issue of verification of the intrafraction respiration induced tumour motion on 
treatment remains one for which there is no consensus. The relatively short duration of 
acquisition of 4DCT contrasts with the far longer duration of treatment delivery. All 
these factors have led to calls for the development of methods of independent 
verification of treatment delivery, in order to pick up the minority of patients with 
significant errors during treatment delivery [124].   
 
Quality assurance in radiotherapy would improve if IGRT allowed for repeated 
verification of tumour position during treatment delivery, either directly or via other 
internal surrogates, during the delivery of the radiation. The position of the carina can 
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be used as an internal surrogate as previous work had shown a good correlation with 
total lung volumes [130] and recent studies have confirmed the correlation between 
the carina and 3D tumour position [131]. Real time tumour tracking using fiducial 
markers is not commonly performed, as insertion can be technically difficult, there is a 
significant risk of pneumothorax [81] and there are high drop-out rates after 
bronchoscopic placement [82]. Electronic portal imaging device (EPID) images have 
been used previously for off-line set up assessment as they enable the internal 
structures during treatment delivery to be visualized [132]. These MV images involve no 
extra dose to the patient and require no prolongation of radiation delivery. However, 
the limited image quality with MV imaging was previously considered a drawback. With 
recent advances in this imaging technology, megavoltage planar images have been re-
evaluated using phantom studies. In their current form, megavoltage planar, 
kilovoltage (kV) planar, and cone beam computed tomography imaging systems, on a 
Varian linear accelerator, have been reported to be of sufficient quality as to allow for 
image-guidance approaches [133]. The possibility of using an MV cine-image, which 
refers to a number of consecutive MV image frames run together to create a movie, has 
been used together with and without implanted fiducial markers for quality assurance 
of gated treatment delivery [134,135].   
 
The hypothesis was that if internal structures could be visualized on MV-cine without 
use of fiducial markers, review of these images could potentially provide off-line 
information on both intrafractional and interfractional motion, with no increase in 
treatment time or radiation dose. Preliminary data from patients supported this 
hypothesis [136]. The aim of the present study was three-fold: firstly to identify 
intrathoracic structures which could be visualized consistently during thoracic 
radiotherapy in stage III NSCLC; secondly, to identify factors which impaired the quality 
of MV-cine; and finally, to assess the residual motion of the same structure (internal 
surrogates) relative to motion observed on the planning 4DCT.  
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4.2 Materials and Methods 
 
Radiation Planning and Delivery 
This was a single-centre retrospective analysis of consecutive patients who had recently 
undergone radical conformal external beam radiotherapy for non-small cell lung cancer 
at the VU Medical Centre (VUMC). All such patients routinely underwent a 4DCT scan, 
performed on a GE Lightspeed RT 16 Multi-slice CT scanner (GE Healthcare, UK) with 
the use of a Varian Real-Time Positioning Management System (RPM; Varian Medical 
Systems, Palo Alto, CA) as described in section 1.3.2. In order to select patients the 
4DCT was reviewed on the Advantage 4D workstation (GE Healthcare, UK) by a 
clinician. The maximum 2D movement of the tumour was measured in the coronal view 
of the movie with the straight line measuring device. Motion measurements were taken 
for the apex of the tumour, the inferior border of the tumour, the lateral edge of the 
tumour and the carina. The maximum tumour movement was noted as the largest of 
the three tumour vectors. Six consecutive patients with tumour movement of over 
2.5mm were included in the analysis.  
All patients had treatment plans, consisting of 5-10 fields using 6 or 15 MV photons. 
Routine daily patient positioning was performed using laser beams and On Board 
Imaging. Radiotherapy was delivered on a Varian 2300 C/D linear accelerator equipped 
with a 120 multileaf collimator, (Varian Medical Systems, Palo Alto, CA) to total doses 
of between 45Gy to 66Gy in fractions of 2-3Gy.  
The key aspect of treatment is that it was delivered using ‘Amplitude Monitored 
Treatment Delivery’ (AMTD), an approach discussed in section 1.3.3, where the RPM 
trace is continuously monitored throughout treatment. Any increase in amplitude over 
the amplitude threshold set at the planning 4DCT causes the radiation beam to 
temporarily stop. AMTD delivery minimizes the likelihood of a systematic difference 
between intra-fraction tumour motion, at 4DCT and during treatment delivery.    
MV-cine were collected from all gantry angles unless two fields had the same gantry 
angle, in which case the field with the largest dimensions was selected on the EPID 
system. The EPID system consists of an image detection unit (IDU) featuring detector 
and accessory electronics, an image acquisition unit containing drive, acquisition 
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electronics and interfacing hardware, and a dedicated workstation for off-line image 
review (Portal Vision 6.5, Varian Medical systems).  The IDU matrix consist 1024 x 768 
pixels (pixel size: 0.39x0.39mm) enabling a 40 x 30 cm2 sensitive area at 145 cm source 
detector distance, i.e. 27.5 x 20.7 cm2 with typical 100 cm isocenter-based radiation 
techniques. During all MV cine acquisition procedures clinical beam parameter settings 
were used (6 MV photon energy; dose rate setting 600 MU/Min.). MV cine imaging 
supports fast image capture of 7-8 image frames per second. Figure 4-1 demonstrates 
an MV cine-image with the tumour highlighted. 
 
Retrospective assessment of MV images 
From each of the first 6 patients selected for review, MV-cine of four consecutive 
fractions were analyzed. To create the MV-cine, initially they were exported, in DICOM 
format from the patient data base system (ARIA Version 8.5, Varian Medical Systems, 
Palo Alto, CA) to the station’s hard-drive. Software developed in-house for the ImageJ 
program was used to resolve the time order for DICOM-based images in exported stacks. 
ImageJ is a Java-based image processing package (http://rsb.info.nih.gov/ij/)  that 
was run under the Windows XP operating system on a Pentium 4 processor with 2 GB on 
board access memory.  
 
• AIM 1: Identification of intrathoracic structures in treatment fields 
Two independent observers, the author and one research physicist, reviewed one 
fraction of radiation belonging to each patient. They were asked if they could identify 
the carina, the hilum and the tumour mass respectively in each field. Only if both 
parties where confident the structure could be identified was the structure noted as 
identifiable. The Beams Eye View (BEV) of the treatment plan with the different 
structures highlighted was available for assistance in identifying structures.   
 
• AIM 2: Factors which impaired the quality of MV cines images 
To identify characteristics of MV-cine that limited their use, when structures could not 
be identified, the observers were asked to document the reasons for this. To assess the 
minimum number of MU’s necessary to encompass a whole breathing cycle, MV-cine 
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were also assessed to see whether a complete respiration cycle had occurred during the 
movie and compared to the MU’s used.  Without an entire breathing cycle, internal 
structure movement would be underestimated, and therefore there is limited value in 
analyzing these images. 
 
• AIM 3: Comparison of motion of a structure on MV cine-image versus motion on 
4DCT. 
Finally, the two-dimensional (2D) motion path for several thoracic structures on MV-
cine images, were measured offline using experimental research software (RPM-Fluoro 
tool kit version 0.7.5, Varian Medical Systems, Palo Alto, CA). The 2D motion path is 
calculated by highlighting the internal structure on the first frame of the MV cine-
image with a reference box and using the markerless tracking tool. The reported 2D 
distance the internal structure moved is the beam’s eye view 2D displacement of 
markers from their expected home position. See Figure 4-2 for a flow chart on creation 
of MV cine-image and analysis of movement. 
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Figure 4-1. Megavoltage image with tumour mass highlighted. 
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The RPM-Fluoro Tool 
A research software tool, the RPM-Fluoro Tool (Varian Medical Systems, Palo Alto, Ca) 
was used to quantitatively assess the motion of all three internal structures. The RPM-
Fluoro Tool was installed on same independent station hard-drive as the MV-cine. To 
review a MV cine-image and to calculate motion, the relevant MV cine-image file was 
selected from hard-drive. This toolkit is able to track obvious soft-tissue targets 
without the need for implanted marker seeds. The markerless registration and tracking 
method is based on spatial template matching. Because the target appearance in 
radiographic images is often quite different at different breathing phases, reference 
images should generally capture target motion over the whole breathing cycle. For 
each incoming frame the registration algorithm goes through a subset of reference 
images to find a best spatial match.  Figure 4-3 demonstrates screen-shots of the RPM-
Fluoro Tool with each of the internal structures highlighted with a reference box.  
Two short assessments were made of the RPM Fluoro-Tool. Firstly there was a phantom 
assessment to validate the measurements it produced, then an assessment for an 
operator difference.  
 
1. Phantom assessment  
An initial assessment of the RPM Fluoro-Tool was performed to validate measurement, 
using a QUASAR TM programmable respiratory motion phantom (Modus Medical Devices, 
London, ON, Canada). QUASARTM phantom consists of a programmable stepper motor 
with a stage, an acrylic body oval, and a cylinder insert that moves in superior-inferior 
directions in the body oval. Motion of the insert is manually set using visualization of a 
gauge and synchronized with the vertical movements of the stage that surrogates chest 
wall motion with 1cm default amplitude. Tumour motion was simulated with 20mm 
peak-to-peak amplitude with cycle duration times of 4 sec, and MV-cine were acquired 
using 100 MU with the same EPID system as described above using clinical settings. The 
MV-cine collected 2.5 respiratory cycles of the moving insert. Motion was assessed using 
the RPM-Fluoro Tool as described above and repeated ten times in order to assess 
measurement accuracy of toolkit with respect to mechanics of the phantom and the 
used MV-cine imaging procedure. An identical storage system to that used with clinical  
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Figure 4-2. Flowchart of steps required to produce an MV cine-image. 
 
 
 
 
 
 
 
 
 
 
MV-cine exported from Aria Version 8.5 
to computer hard drive. 
MV-cine imported into ImageJ for sorting into 
chronological order on computer hard drive. 
MV-cine opened in RPM 
Fluoro Tool. 
Reference Box placed around 
internal structures using RPM 
Fluoro Tool and motion 
calculated. 
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Figure 4-3. Screen-shots of the RPM-Fluoro Tool with each of the internal structures 
highlighted with a reference box. From the top; primary tumour, carina and hilar 
structure respectively. 
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cine-images was used with an average image of every two frames (image pairs) making 
up the MV cine-image. 
 
2. Assessment of interclinician variability in motion calculation. 
The results derived using the tool with two different users were assessed. The motion 
of the primary tumour, hilum and carina were assessed in 6 MV-cine by two 
independent observers. A patient with significant motion was selected so that the 
potential for differences in motion would be larger. The two different motion 
measurements for each structure in each cine-image were compared to ensure the tool 
was not user dependent.  
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4.3 Results 
 
RPM-Fluoro Tool Analysis 
The mean peak-to-peak amplitude of the phantom measured from 20 imaged full 
respiratory cycles was 19.5 mm (range 19.3 to 19.7mm). There are a number of factors 
which may affect this result. As discussed above the predefined motion of the phantom 
was manually set using a gauge that will introduce a small offset value. In addition the 
standard deviation of 0.16 mm is smaller than the pixel dimension 0.26mm at 100cm 
isocenter level. The range in measurements are likely introduced due to measuring 
object position from averaged image pairs, as depending on the velocity of object, the 
average image will show slightly variable blurring. Taking all these effects into account 
we felt confident the RPM-Fluoro Tool accurately measured the motion of object on 
MV-cine. 
 
The mean difference in tumour, hilar structure and carina motion between the two 
observers was 0.4mm (range 0.0 to 0.9mm), 0.6mm (0.1 to 1.0mm), 0.3mm (range 0.1 
to 0.8mm) respectively. None of the analyses demonstrated a difference in structure 
motion between observers larger than 1mm.  
 
The Clinical MV-cine Analysis 
Six patients with either stages IIIA or IIIB lung cancer were identified for the analysis, 
and tumour characteristics are summarized in Table 4-1.   
 
• AIM 1: Identification of intrathoracic structures in treatment fields 
Each treatment plan consisted of between 5 – 10 fields. In the six patients there were a 
total of 25 fields. These 25 fields were assessed on 4 consecutive days, so in total 100 
MV-cine were assessed. 
The most commonly recognizable structure was the carina, which was situated within 
96 of the fields. With the guidance from the corresponding digitally reconstructed 
radiograph (DRR), the carina was identifiable in 80 of the 96 MV-cine (83%). The 
primary tumour mass could be identified in 68 of the 100 cine-images (68%). The hilum 
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was situated in 88 fields and could be identified in 64 (73%). It is important to highlight 
that in this group of patients, 4 of the 6 patients had hilar tumours, which may have 
resulted in the hilum being more readily visible. There were 60 oblique fields. In these 
fields, the carina was visible in 80%, the tumour mass in 32% and the hilar mass in 50% 
of the fields it was situated in. 
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Table 4-1. Patient Characteristics 
 
LMZ – left mid zone. RMZ – right mid zone. RLZ – right lower zone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Tumour 
Stage 
Nodal 
Stage 
 
Primary Tumour 
maximum diameter 
(cm) 
Location 
Total Dose 
(cGy) 
Dose per 
fraction 
No of 
Fields 
        
Patient 1 T4 N3 7.2 RMZ 4500 300 5 
Patient 2 T3 N2 4.2 RMZ 6000 200 10 
Patient 3 T3 N2 7 RMZ 6600 200 5 
Patient 4 T4 N2 11 RMZ / RLZ 6000 200 7 
Patient 5 T3 N2 5.8 RMZ 5775 275 5 
Patient 6 T3 N2 7.5 LMZ 4500 300 5 
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• AIM 2: Factors which impaired the quality of MV cines images 
Among the factors which limited the ability to visualize the carina were a dense 
mediastinal shadow of similar density, MLC obliterating almost the entire field and a 60 
degree dynamic wedge obliterating the field before any structures could be visualized. 
Although the placement of a treatment bed bar over a structure did not inhibit 
identification, it prevented the assessment of structure movement. The RPM Fluoro Kit 
follows the densest object in the reference box and with an immobile treatment bed 
bar, it continuously registered no movement.  
Of the 100 cine-images, the number of breathing cycles visualized using the RPM fluoro 
tool could be assessed in 91. Respiratory motion could not be visualized in five cine 
recordings due to all the visible movement being due to heartbeat and in four cine-
images of the same field, due to the MLC taking up almost the entire field. Of these 91 
fields, 70 included at least one complete respiratory cycle (77%). The median number 
of intra-fraction respiratory cycles observed was 2 (range, 1-6). Of the 21 fields that 
did not include a whole breathing cycle, 16 had <30MU in the field, in 4 although there 
were 40MU, a 60 degree wedge obliterated the field before any assessment could be 
made. In summary, without a wedge present, any field with >30MU’s is likely to include 
an entire breathing cycle. 
 
• AIM 3: Comparison of motion of a structure on MV cine-image versus motion on 
4DCT.  
The median 2D movement of the primary tumour was 5mm (range, 1 – 15mm) [Table 4-
2] in comparison to the median movement of the primary tumour on the 4DCT of 10mm 
(range, 7 – 15mm). The median 2D motion of the carina in all assessable fields during 
AMTD was 3mm (range, 1 – 10mm) [Table 4-3] in comparison to the median 2D motion 
measured on the 4DCT's of the same patients, which moved 7mm (range, 4- 10mm).  
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Table 4-2. Two-dimensional intra-fraction tumour motion (mm) during delivery of 
Amplitude Monitored Treatment Delivery. 
 
 
  
  
Intra-fraction Tumour Motion during Amplitude Monitored Treatment Delivery (mm) 
  
  
Fraction 1 
  
Fraction 2 
  
Fraction 3 
  
Fraction 4 
 
 
4DCT 
motion 
 
Mean S.D. 
 
Mean S.D. 
 
Mean S.D. 
 
Mean S.D. 
 
Patient 1 
 
6.9 
 
 
6.6 
 
1.8 
 
 
4.6 
 
1.0 
 
 
4.6 
 
0.8 
 
 
4.4 
 
0.8 
Patient 2 6.5  1.6 0.6  2.2 0.9  2.6 0.2  2.0 0.3 
Patient 3 7.8  9.4 3.7  6.2 2.3  9.1 0.8  7.3 2.9 
Patient 4 9.8  11.0 3.9  5.3 0.3  5.2 1.3  9.9 2.4 
Patient 5 15.0  8.7 1.6  10.0 1.4  8.9 0.1  7.4 1.0 
Patient 6 10.5  5.7 1.1  3.8 0.3  7.0 2.3  7.6 1.4 
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Table 4-3. Two-dimensional intra-fraction carina motion during delivery of Amplitude 
Monitored Treatment Delivery. 
 
 
 
 
  
  
Intra-fraction Carina Motion during Treatment Delivery 
  
  
Fraction 1 
  
Fraction 2 
  
Fraction 3 
  
Fraction 4 
 
4DCT 
motion 
 
Mean S.D.  Mean S.D.  Mean S.D.  Mean S.D. 
Patient 1 3.7  2.3 0.9  2.4 1.2  2.2 0.5  1.9 0.9 
Patient 2 6.9  1.9 0.7  2.3 0.3  2.5 0.8  1.6 0.4 
Patient 3 10  6.8 2.1  5.4 1.5  6.4 1.9  4.2 1.9 
Patient 4 7.8  3.4 0.9  3.0 0.4  4.1 1.1  2.8 0.1 
Patient 5 7  3.8 3.1  3.9 0.4  2.5 0.9  4.0 3.1 
Patient 6 5.6  1.3 0.0  1.6 0.8  1.9 0.9  1.5 0.6 
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4.3 Discussion 
 
This study shows that intrathoracic structures can be visualized in MV-cine for a 
significant proportion of patients undergoing radiotherapy for stage III lung cancer, 
both in AP and oblique fields. The frequency with which structures were identified was 
higher than is generally expected. This may be due to the images being cine-images 
rather than single frames as both observers noted that the identification of structures 
was significantly easier with the cine-image rather than single frames. The use of the 
BEV also contributed to a higher identification rate. This is similar to having the 
structures superimposed onto the cine-image which is routine practice in other 
verification images.  
 
Factors which impair the ability to identify structures on MV images were identified and 
these included selection of dynamic wedge angles above 60º, fields with large 
quantities of MLC, and delivery of ≤30MU. The position of the treatment bed bar 
limited the assessment of internal structure movement. We are continuing to collect 
data on MV-cine; these guidelines have enabled us to only image fields that will allow 
motion assessment. 
 
The use of the RPM fluoroscopy tool permits calculation of intrafraction motion of these 
internal structures. In order for MV-cine to be used as an independent verification tool, 
other motion must be assessed such as interfraction motion and set-up error. This can 
currently be assessed by superimposing structures from the planning scan onto the MV 
cine-image and making manual measurements, however it is a time-consuming, 
complicated process. In order for MV-cine to be used routinely as an independent 
verification tool, assessing inter and intra fraction motion as well as set-up variation, 
significant software development would be required to streamline this process. As this 
was only an explorative study, only observations can be made on the analysis of 
internal structure movement. 4DCT remains a snap shot of tumour motion and it is 
therefore reassuring to see that the majority of intrafraction motion on treatment was 
less than the motion visualized in the 4DCT. This is reassuring because if the 4DCT over 
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estimates intrafraction motion, and as a result a larger margin and more adverse 
effects occur, at least there is no geographical miss of the tumour due to 
underestimation of tumour motion at 4DCT. One can speculate as to why intrafraction 
motion is less on treatment than during 4DCT. It is possible that patients are more 
anxious during the 4DCT as it is their first visit to the department and they are unsure 
of proceedings. This may result in a slightly increased tidal volume, increasing tumour 
motion. As they attend daily, their anxiety disappears and as a result their tidal volume 
and tumour motion. These are speculations however the reason for this fall in motion 
requires further investigation. It must be noted that in this study, AMTD may have 
prevented unusually large respiration cycles from being treated. In centres where AMTD 
is not routinely used, this verification tool would highlight those patients with unusually 
shallow breathing at 4DCT scanning, resulting in a systematic error due to 
underestimation of tumour movement. It is also of interest to note that different fields 
provided different amounts of movement, indicating that analysis of motion on MV-cine 
from one field alone is not necessarily representative of all the treatment. With the 
knowledge of the factors that allow a good MV cine-image, the VUMC are continuing to 
collect data in a larger group of the lung cancer patients in order to draw some 
conclusions on intra-fraction motion. 
 
Although the use of techniques such as IMRT do not support acquisition of MV-cine, such 
plans can be adapted to include at least one non-IMRT AP field which would allow the 
capture of MV images as a verification tool [137]. 
 
In conclusion, internal anatomy can be reliably identified using MV-cine of the thorax. 
This allows for residual motion to be measured during the delivery of image-guided 
radiotherapy. Our analysis highlights the potential of these images for use as an 
independent verification tool but in order for quick-step assessment of the tumour 
intrafraction and interfraction motion, as well as setup variation, significant software 
development is required.  
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5. AMPLITUDE MONITORED TREATMENT DELIVERY (AMTD): A RESPIRATORY-MOTION 
MANAGEMENT TECHNIQUE AIMED TO LIMIT VARIATIONS IN INTRA-FRACTION MOTION 
BETWEEN PLANNING AND TREATMENT DELIVERY. 
 
 
5.1 Introduction 
 
In patients whose tumours show significant respiration-induced motion, 4DCT identifies 
those who may benefit from respiratory-gated radiotherapy (RGRT) by identifying 
potential windows within the respiratory cycle, for gated-delivery [87,138]. However, 
this form of RGRT is not suitable for all patients. There is a clinical benefit in only a 
minority of patients, whose tumours show significant motion [139]. In addition a regular 
respiratory cycle is required and although the reproducibility can be improved on with 
respiratory coaching [140], it remains unachievable for some patients.  
 
In order to exclude the possibility of acquiring non-representative motion data on the 
4DCT, as well as to overcome limitations of traditional forms of RGRT, the VUMC 
implemented a novel form of respiratory management ‘Amplitude Monitored Treatment 
Delivery’ (AMTD) which is illustrated in Figure 1-7. This approach is essentially 
respiratory gating with a larger duty-cycle, where the radiation is delivered while the 
intra-fraction surrogate motion is equal, or less, to what was recorded at 4DCT and 
automatically withheld when the intra-fraction motion exceeds that seen at 4DCT. 
AMTD aims to limit the possibility of a geographic miss arising when a larger tumour 
amplitude occurs during treatment delivery, than what was observed in the planning 
4DCT.  
 
In the feasibility study of MV-cine, the MV-cine images demonstrated that in the 
majority of patients there was more motion on the 4DCT than on the MV-cine, which is 
preferable as it prevents geographical miss. As we have now confirmed that MV-cine 
can be used to monitor motion, and have identified the limiting factors so they can be 
avoided, we embarked on a project to verify the use of AMTD using MV-cine images. 
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The implementation of the AMTD technique is described and MV-cine images were 
collected and analysed to verify the AMTD treatment.  
 
 
5.2 Materials and Methods 
 
Patient selection, image acquisition and target definition 
Data from twenty consecutive patients who completed AMTD treatment for node-
positive, non-small cell lung cancer at the VUMC, Amsterdam, The Netherlands, were 
retrospectively analyzed. Patients are eligible for AMTD if their primary lung tumours 
showed limited motion (generally ≤10 mm) on 4DCT scan, or if the tumour motion 
exceeds 1cm but they are unable to maintain a regular respiratory cycle despite 
respiratory coaching. For those patients with tumour motion ≥1.0 cm and/or when a 
reduction in the volume of lung tissue receiving threshold doses of 20 Gy (V20) is 
expected with phase gating at end-inspiration lung volume, phase-based gated delivery 
is employed. In three of the 20 patients, the maximum motion of the primary tumour 
exceeded 11 mm (13.2-13.8 mm), but the patients were unable to maintain a regular 
respiratory cycle hence AMTD treatment was chosen. Patient characteristics are 
summarized in Table 5-1.  
 
All patients undergoing high dose thoracic radiotherapy at the VUMC undergo a single 
4DCT scan on a GE Lightspeed RT 16 Multi-slice CT scanner (GE Healthcare, UK) during 
quiet uncoached respiration as previously described in Chapter 4.2. The respiratory 
waveform is co-registered using the Varian Real-Time Positioning Management System 
(RPM; Varian Medical Systems, Palo Alto, CA). The 10 phases of the 4DCT were created 
and reviewed on the Advantage 4D workstation (GE Healthcare, UK). All phases where 
the tumour or lymph nodes lie in the extremes of motion were identified and used to 
create a gross tumour volume encompassing the tumour in all phases of the respiratory 
cycle on Eclipse Planning System (Varian Medical Systems, Palo Alto, CA). Subsequently, 
a margin of 5mm was added for microscopic disease and 5mm for set-up error was  
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Table 5-1. Patient characteristics. 
 
 
  
Tumour  
Stage 
Nodal  
Stage 
 
Tumour Size 
 (max. diameter  
in cm) 
Location 
Total Dose 
(cGy) 
Dose per 
fraction 
No of 
Fields 
 
Patient 1 
 
T4 
 
N3 
 
7.2 
 
RMZ 
 
4500 
 
300 
 
5 
Patient 2 T3 N2 4.2 RMZ 6000 200 10 
Patient 3 T3 N2 7 RMZ 6600 200 5 
Patient 4 T4 N2 11 RMZ / RLZ 6000 200 7 
Patient 5 T3 N2 5.8 RMZ 5775 275 5 
Patient 6 T3 N2 7.5 LMZ 4500 300 5 
Patient 7 T4 N1 7.8 LMZ 6600 200 5 
Patient 8 T4 N2 10.35 LMZ 5000 200 6 
Patient 9 T4 N2 11.8 LMZ 4500 300 6 
Patient 10 T2 N2 2.8 RMZ 6000 200 7 
Patient 11 T2 N2 5.75 RMZ 6000 200 6 
Patient 12 T2 N2 4.3 LMZ 6000 200 6 
Patient 13 T4 N3 5.7 RLZ 6000 200 5 
Patient 14 T4 N3 9.15 mediastinal 4600 200 5 
Patient 15 T3 N2 9.15 RUL 6600 200 7 
Patient 16 T3 N2 5.3 LLL 6600 200 6 
Patient 17 T4 N3 5.19 LMZ 5000 200 5 
Patient 18 T1 N2 1.8 RMZ 5000 200 7 
Patient 19 T3 N1 8.5 RUL 5000 200 4 
Patient 20 T4 N1 7.3 RUZ 6600 200 4 
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added to create the planned target volume (PTV). All patients have treatment plans 
consisting of 5-10 fields using 6 or 15 MV photons.  
 
Treatment delivery 
Radiotherapy was delivered on a Varian 2300 C/D linear accelerator equipped with a 
120 multileaf collimator, (Varian Medical Systems, Palo Alto, CA) to total doses of 
between 45Gy in pre-operative cases to 66Gy in radical cases, in fractions of 2-3Gy.  
 
During treatment delivery, no form of respiratory coaching was undertaken as a regular 
wavelength and amplitude are not required for AMTD treatment. Patient positioning 
was performed using laser beams and either an orthogonal pair of kV images, taken in 
the anterior-posterior and lateral position, or kV cone-beam CT (CBCT) images. An 
online bony match was performed followed by a shift to eliminate the disparities. The 
original volumes are superimposed on the images and a visual check was made to 
ensure the tumour lay within the GTV. The RPM system was used to record a respiratory 
waveform. On each treatment day, the end-expiration position of the respiratory trace 
was programmed as the baseline for the amplitude threshold. The maximum amplitude 
of the respiratory trace observed at the time of 4DCT was specified as the maximum 
acceptable respiratory trace amplitude during treatment. During delivery, if the 
respiratory trace amplitude exceeded the maximum acceptable amplitude, the linac 
was programmed to automatically turn off. Once the respiratory trace fell back 
between these points, irradiation was resumed. 
 
Intra-fractional image acquisition 
The acquisition of MV-cine is identical to that described in section 4.2 with a step by 
step illustration of the steps involved in the production of MV-cine in Figure 4-2.  
 
During all clinical MV-cine acquisition procedures, clinical beam parameter settings 
were used (6 MV photon energy; dose rate setting 600 MU/min). MV-cine imaging 
supports fast image capture of 7-8 image frames per second. The beams that would 
give the best image quality were selected by using fields closest to gantry angles 0 or 
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180 degrees, with large dimensions, large numbers of monitor units and minimal 
wedges. For storage purposes every two frames were saved as an average frame. This 
prevented overload of the hard drive on which the images were saved. 
Six MV-cine from different fractions were randomly selected and analysed for each 
patient. Initially they were exported, in DICOM format from the patient data base 
system (ARIA Version 8.5, Varian Medical Systems, Palo Alto, CA) to an independent 
station’s hard-drive. Software developed in-house for the ImageJ program was used to 
resolve the time order for DICOM-based images in exported stacks. ImageJ is a Java-
based image processing package (http://rsb.info.nih.gov/ij/) that was run under the 
Windows XP operating system on a Pentium 4 processor with 2 GB on board access 
memory.  
 
The number of available respiratory cycles captured in each MV cine-study was noted.  
 
Assessment of 4DCT Motion  
For the purposes of this study, the 4DCT motion of the tumour, hilum and carina was 
measured at an Advantage 4D workstation (GE Healthcare, UK) by a clinician. The 
maximum 2D movement of all three internal structures was measured in the coronal 
view of the movie with the straight line measuring device. When assessing tumour and 
hilar structures, the motion measurements were taken for the apex, the inferior border 
and the lateral edge of the structures. The maximum movement was noted as the 
largest of the three measurements.  
 
Assessment of motion during AMTD 
Each MV cine-image was reviewed using the RPM-Fluoro Tool as described above. 
Following the calculation of motion of each internal structure, the MV cine-image was 
reviewed with the reference box moving in tandem with the internal structure, to 
ensure the reference box encompassed the internal structure throughout the 
respiratory cycle. If the reference box did not follow the internal structure well, the 
process was repeated. The motion was noted when the internal structure and the 
reference box moved together coherently. 
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5.3 Results 
 
Clinical Analysis 
Tumour characteristics of all 20 patients are summarized in Table 5-1. Six MV-cine were 
analyzed for each patient. Both observers identified images of the primary tumour in 
95% of cases, although it must be noted that 12/20 patients (60%) had primary hilar 
tumours. Separate hilar structures were identified in the other 40% of patients with a 
primary tumour located elsewhere. Of these, only 88% had hilar structures that were 
consistently identifiable by both observers. The carina was visible in 95% of MV-cine. 
The mean number of respiratory cycles in all 120 MV-cine was 2.45 cycles (range 1 to 
6), as assessed by peak-to-peak amplitudes, allowing for tumour amplitude assessment 
in all the MV-cine.  
 
In 19 patients, the 2D superior-inferior primary tumour movement was calculated on 
the 4DCT. Motion of the primary tumour was not assessed for a primary mediastinal 
tumour. The mean motion of the primary tumour on 4DCT was at 7.3mm (range 2mm to 
13.8mm). Of those 7 patients without hilar tumours, the mean movement of the hilar 
structure was 11.0mm (range 4.2mm to 15.1mm). The mean carina movement was 
calculated from measurements from all patients and was 6.8mm (range 1.8mm to 
21.2mm). 
 
Tables 5-2, 5-3 and 5-4 demonstrates the tumour, hilar structure and carina motion 
seen on the MV-cine  of each patient respectively in comparison to the internal 
structure motion seen at 4DCT. A total of 6 MV-cine were studied per patient. Mean 
motion of primary tumour, carina and hilum on 4DCT was at 7.3mm (range 2-13.8mm); 
6.8mm (1.8-21.2mm) and 11.0mm (4.2-15.1mm) respectively. Corresponding motion 
during AMTD was 4.1mm (0.6-13.6mm); 2.7mm (0-10mm) and 6.0mm (1.8-14.4mm), 
respectively.  
 
The tumour and the hilar structures were tracked well by the RPM-Fluoro Tool. The 
carina often had areas of the treatment bed or a vertebrae in the field, all which make 
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tracking impossible as the reference box follows the immobile high dense structure, 
hence only 34%, (39 from 114) of the MV-cine  with visible carina's could be tracked. 
 
The number of studies in which the primary tumour motion on an MV cine-image 
exceeded that on the corresponding 4DCT was 16 of the 114 (14%) cine-images. 
Interestingly, nearly all were acquired from Patients 1 and 2, indicating a systematic 
error in 10% of patients. The remaining MV-cine demonstrating more motion than the 
4DCT, were sporadically distributed between all the other patients and hence are likely 
to represent random errors.  
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Table 5-2. Primary tumour motion on 4DCT and during AMTD treatment. 
 
  
 
4DCT Tumour 
Motion 
(mm) 
 MV cine-image Tumour Motion (mm) 
    
 
Mean 
 
 
S.D. 
 
 
Min 
 
 
Max 
Patient 1  5.9  8.2  3.2  4.5  12.8 
Patient 2  2.0  3.9  1.5  2.0  6.3 
Patient 3  6.9  3.8  0.9  2.9  5.1 
Patient 4  10.5  6.9  1.6  5.0  8.9 
Patient 5  9.8  7.6  2.8  4.6  12.6 
Patient 6  7.8  2.1  0.3  1.7  2.4 
Patient 7  6.4  2.5  0.4  2.0  2.9 
Patient 8  4.9  2.6  0.6  1.7  3.3 
Patient 9  5.4  0.9  0.2  0.6  1.1 
Patient 10  7.6  4.7  2.1  2.0  7.8 
Patient 11  3.0  1.9  0.8  1.2  3.5 
Patient 12  13.2  9.0  3.7  5.0  13.6 
Patient 13  Mediastinal tumour therefore analysis not undertaken 
Patient 14  13.4  4.2  1.2  2.3  5.8 
Patient 15  8.3  3.4  1.3  2.0  5.1 
Patient 16  4.9  4.3  1.5  2.2  6.4 
Patient 17  13.8  5.1  1.1  3.5  6.5 
Patient 18  5.9  2.7  0.9  1.7  4.3 
Patient 19  3.4  0.8  0.2  0.6  1.0 
Patient 20  6.9  2.6  1.0  1.6  4.4 
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Table 5-3. Hilar Structure motion on 4DCT and during AMTD treatment. 
 
 
 
  
 
4DCT Hilar 
Motion 
 MV cine-image Hilar Structure Motion (mm) 
  (mm)  Mean  S.D.  Min  Max 
Patient 1  15.1  10.9  2.8  6.1  14.4 
Patient 2  15.0  7.8  2.3  5.2  11.5 
Patient 10  8.1  8.1  3.0  4.7  11.7 
Patient 11  12.8  2.1  0.2  1.8  2.3 
Patient 12  9.9  6.3  3.3  2.3  10.5 
Patient 15  11.8  4.6  1.5  3.2  7.3 
Patient 19  4.2  2.4  0.5  1.8  2.8 
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Table 5-4. Carina motion on 4DCT and during AMTD treatment. 
 
 
 
 
  
 
4DCT Carina 
Motion 
 MV cine-image Carina Motion (mm) 
  (mm)  Mean  S.D.  Min  Max 
Patient 1  7.0  2.2  0.5  1.5  2.6 
Patient 2  10.0  5.7  1.6  4.0  8.3 
Patient 3  5.6  Cannot see carina 
Patient 4  3.7  0.9  0.3  0.6  1.2 
Patient 5  7.8  2.9  1.0  2.0  4.4 
Patient 6  6.9  2.0  0.8  1.4  3.1 
Patient 7  7.3  2.0  0.0  2.0  2.0 
Patient 8  5.4  1.2  0.5  0.6  2.0 
Patient 9  4.2  1.1  0.0  1.1  1.1 
Patient 10  6.0  3.1  1.3  2.2  4.0 
Patient 11  4.4  2.4  1.5  0.6  4.5 
Patient 12  4.9  2.6  2.1  0.0  5.1 
Patient 13  4.4  4.2  1.7  2.2  7.2 
Patient 14  4.7  2.0  0.9  1.0  3.5 
Patient 15  8.9  5.8  2.7  1.6  9.1 
Patient 16  6.9  RPM-Fluoro Tool failed to track carina 
Patient 17  8.6  5.1  4.3  2.3  10.0 
Patient 18  6.9  2.3  2.5  1.0  7.5 
Patient 19  1.8  1.2  0.6  0.6  2.0 
Patient 20  21.2  RPM-Fluoro Tool failed to track carina 
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5.4 Discussion 
 
Our study highlights the importance of independently verifying novel radiotherapy 
techniques. We used MV-cine to study intra-fraction motion; an approach has been 
reported to be a feasible and clinically effective method of independent verification 
[141,142,143]. The quality of MV-cines is supported by the fact that tumour and carina 
were visualized in 95% of all analyzed images, and the hilum in 88%. In cases where the 
primary tumour is not visualized, the carina and the hilar structure can act as 
surrogates for tumour motion [126]. In 34% of MV-cines, difficulties were observed in 
tracking the carina, mainly due to the bed frame in the field. The latter was solved by 
repositioning the former out with the field for future fractions. Use of MV-cines were 
not possible using conventional IMRT plans, but hybrid IMRT plans that use at least one 
non-IMRT anterior field would allow an MV cine-image for independent verification 
[144].   
 
The motion demonstrated in this group of locally advanced tumours can be compared 
to that of Liu et al [145]. Liu et al assessed the motion of 166 locally advanced tumours 
and found that the population averages of tumour motion were 0.50cm in the superior-
inferior in comparison to our mean motion of 0.74cm on 4DCT. They noted the 
percentage of patients with >0.5cm of motion as 39.2% and >1.0cm of motion as 10.8% 
respectively. In our series the tumours moved more with motion >0.5cm and >1.0cm in 
74% and 21%. The slightly larger motion seen in our series, may be in part due to a 
smaller sample size however despite this, it is unexpected, as those with large motion 
who were suitable for RGRT were excluded.  
 
AMTD appears to be a suitable approach for the majority of patients who are not 
candidates for traditional RGRT due to limited tumour motion, irregular breathing or 
intolerance of coaching. It does not require mandatory respiratory coaching, as 
maintaining a reproducible wavelength and amplitude is not integral to delivery, and is 
more efficient than traditional RGRT as the duty-cycle is larger. With AMTD delivery, 
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only 10% of patients have consistently more intra-fraction tumour motion on treatment 
than at 4DCT.  
 
The AMTD technique is not without limitations. Although correlation coefficients 
between tumour and external surrogates have been reported to be as high as 87% in the 
superior-inferior direction [85] and 81% in all directions [88], little or no correlation is 
seen in a minority of patients. It requires further study to investigate whether the 10% 
of patients with consistently larger intra-fraction tumour motion on during treatment 
are those with little or no correlation. If a lack of correlation is the cause of the larger 
intra-fraction motion, new software tools are available to assess the correlation 
between external surrogate and internal motion prior to treatment to identify those in 
whom AMTD is not applicable [146]. If there is an alternative explanation this study 
offers a simple, radiation free method of identifying them with use of MV-cines, 
although improved software would be required as the current process is time-
consuming and not feasible for routine clinical use. The alternative imaging techniques 
that can be used on-line to assess intra-fraction motion are fluoroscopy [49,147] or 4D-
CBCT [65], however the disadvantages of these include the additional radiation dose 
and treatment time. Also, the intra-fraction motion seen during online imaging does 
not necessarily represent the motion during treatment, only prior to treatment, at 
which time the patient may be breathing differently for a variety of reasons including 
anxiety due to the gantry rotating or additional noise.  
A further limitation of AMTD is the lack of assessment of baseline shifts. Our current 
technique of online CBCT, utilizes the fact a CBCT is taken over a number of respiratory 
cycles, hence creating an image demonstrating the tumour in the mean position. The 
visual check comparing the tumour on the CBCT to the planning gross tumour 
throughout the respiratory cycle highlights any obvious baseline shift in mean position 
of the tumour. The MV-cine could potentially be used to make a comment on baseline 
position however due to lack of integration into the planning and delivery system, 
software limitations make it is impossible to confidently comment on baseline shift at 
present. 4D-CBCT is currently the gold standard for online assessment of baseline shift, 
however the limitations are noted above.  
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There may be concerns that AMTD requires additional time for treatment delivery due 
to steps such as placement of an infrared marker box, assessment of the respiratory 
waveform, and the intermittent treatment beam. However our treatment slots have 
not increased with the introduction of AMTD and the 15 minute treatment slots are 
identical to non-AMTD thoracic treatments.  
 
AMTD offers a novel method of limiting variation in intra-fraction motion and is 
applicable to the majority who are not suitable for traditional forms of RGRT. Our 
findings also add to the growing body of data showing the potential of MV-cine as a 
verification tool in the delivery of thoracic radiotherapy. 
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6. INVESTIGATION OF THE CLINICAL BENEFIT OF RESPIRATORY GATED 
RADIOTHERAPY (RGRT) IN LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER 
(NSCLC). 
 
 
6.1 Introduction 
 
Traditional forms of RGRT such as phase-based or amplitude-based RGRT, have been 
shown to reduce the size of the PTV when compared to the standard 4D PTV [91]. The 
theoretical advantages are: reduction in toxicity; potential for dose escalation; and 
fewer patients having radical treatment withheld on account of large volumes or 
unacceptable toxicity parameters.  
 
Despite the enthusiasm regarding this new technique, it is essential to be aware of the 
potential disadvantages which are discussed in detail in section 1.3.4.1.  
 
In view of these concerns and controversies, it is imperative to quantify the clinical 
benefit to patients that RGRT provides, when compared to continuous (non-gated) 
4DCT treatment to save embarking unnecessarily on complex and costly techniques. As 
yet, there are no randomised clinical trials and only one paper suggesting there is a 
reduction in lung V20 with RGRT [91]. There is no consensus on which parameters can 
predict an improvement in clinical outcome when comparing RGRT to continuous 
irradiation of 4DCT; however the toxicity parameters that are routinely used in clinical 
practice can be used as surrogates. These include the volume of lung receiving 20Gy 
(V20 lung); volume of lung receiving 5 Gy (V5 lung); mean lung dose (MLD); and volume 
of oesophagus receiving 50Gy (V50 oes). As there is no consensus on the best lung 
parameters, a number of different parameters were used that have all been 
demonstrated to correlate with radiation pneumonitis [148,149,150]. There is no 
consensus on the toxicity parameter to be used with the oesophagous, some use the 
length of oesphagous irradiated others the V50 or V55. V50 was selected as a recent 
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study of 100 patients assessing different dosimetric parameters that identified this as 
the one that best correlated with toxicity [151]. If the toxicity parameters are reduced 
with RGRT in comparison to continuous (non-gated) 4DCT treatment, three theoretical 
benefits of RGRT could be achieved: toxicity will decrease; there is potential for dose 
escalation; and more patients would have toxicity parameters within the acceptable 
levels to proceed to radical radiotherapy. 
 
There were four aims of this study (1) quantify the improvement in clinical outcome of 
RGRT in comparison to continuous (non-gated) 4DCT irradiation, by using toxicity 
parameters as surrogates for clinical outcome; (2) assess the correlation between 
tumour motion and benefit of RGRT with a view to identifying a threshold of tumour 
motion where RGRT should be considered; (3) compare the benefit of inspiration RGRT 
to expiration RGRT; (4) assess the benefit of RGRT when smaller set-up margins (CITV 
to PTV margin) are used.  
 
 
6.2 Materials and Methods 
 
Patient Data Acquisition. 
CT image datasets of consecutive node-positive lung cancer patients were reviewed 
retrospectively. These patients had previously undergone 4DCT for treatment planning 
and completed routine radical radiation to a dose of 55Gy in 20 fractions with 
continuous (non-gated) 4DCT treatment. In order to select patients for the study, an 
assessment of tumour motion was undertaken using the cine-movie facility on an 
Advantage 4D workstation (GE Healthcare, UK). The maximum distance the apex and 
inferior border of the primary tumour moved during the respiration cycle was measured 
using the straight line measuring device. Any patient with >5mm craniocaudal tumour 
movement at either of these points was eligible. Fifteen consecutive patients were 
selected. 
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The 4DCT image acquisition has been reported in detail in Section 2-2. In brief, patients 
were scanned on a GE Lightspeed RT 16 Multi-slice CT scanner (GE Healthcare, UK) with 
scanning parameters set at 120 kV, 20mA with a slice thickness of 2.5mm. Patients 
were audio-coached, with the rate of respiration set at their initially recorded 
respiratory rate. The RPM System is used to record a trace of the patient’s respiratory 
cycle during acquisition of the scan. In each couch position, the scanner acquired 10 
consecutive scans over the course of one breathing cycle. These scans were sorted 
using the Advantage 4D workstation into 10 phase-bins representing the 10 phases of 
the respiratory cycle. 
 
 
Delineation of Targets. 
The author delineated 3 different GITVs for each patient using Varian Eclipse 
Treatment Planning System, software version 8.6 (Varian Medical Systems, Palo Alto, 
CA). The different GITVs were created to represent, the full extent of respiratory 
motion, end-inspiration and end-expiration. 
 
To delineate the GITV for gating in end-expiration, Exp_GITV, the cine movie of all 
phase-bins was reviewed. The Exp_GITV was delineated using the phase-bin with the 
tumour in the most superior position. The Exp_GITV was then reviewed in the 
surrounding 2 phase-bins and enlarged to encompass any additional tumour visualised. 
This additional tumour visualised represents tumour movement during the imaging of 
the 3 expiratory “bins”. The GITV for gating in end-inspiration, Insp_GITV, was created 
in the same way however this time identifying the phase-bin with the tumour in the 
most inferior position and the surrounding 2 phase-bins. A composite of Exp_GITV and 
Insp_GITV was created to represent the positional variation of the tumour throughout 
all phases of respiration (4D_GITV). A margin of 5mm was added to encompass 
microscopic invasion to each of these GITVs and then two different planned target 
volumes (PTV) for each GITV were created using set-up margins of 5mm and 10mm 
respectively. This created 6 different PTVs: 
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• 4D_PTV (10mm margin) – 4D_GITV with a 5mm for microscopic spread and 
10mm set-up margin. 
• Insp_PTV (10mm margin) – Insp_GITV with a 5mm for microscopic spread and 
10mm set-up margin. 
• Exp_PTV (10mm margin) - Exp_GITV with a 5mm for microscopic spread and 
10mm set-up margin. 
• 4D_PTV (5mm margin) - 4D_GITV with a 5mm for microscopic spread and 5mm 
set-up margin. 
• Insp_PTV (5mm margin) Insp_GITV with a 5mm for microscopic spread and 5mm 
set-up margin. 
• Exp_PTV (5mm margin) - Exp_GITV with a 5mm for microscopic spread and 
5mm set-up margin. 
 
Organs at Risk Delineation and Treatment planning.  
The two 4D_PTVs had the dose calculation undertaken on an Average Intensity 
Projection (Ave-IP) data-set, created using all ten phase-bins. The two Insp_PTVs were 
calculated on an Ave-IP data-set created using the three phase-bins representing end-
inspiration and the two Exp_PTVs were calculated on an Ave-IP data-set created using 
the three end-expiration phase-bins. The whole lung was delineated on each of the 
different Ave-IPs using automatic segmentation followed by manual editing if required. 
To calculate the lung toxicity parameters the whole lung of the appropriate Ave-IP 
minus the relevant PTV was used in each plan. The oesophagus was delineated from the 
oropharynx to the oesophageo-gastic junction. 
 
Six treatment plans were generated for each patient by the author. All plans consisted 
of 55Gy in 20 fractions delivered using 3-5, 6MV photon beams with 100% prescribed to 
isocentre.  For each patient, an initial plan was created for the 4D_PTV. Most 
treatments used beams at gantry angles of 0, 60-70 and 120-130 degrees from the 
vertical. Additional boost fields were used to boost the periphery of the PTV where 
necessary. The plan was optimized to cover as much of the PTV as possible with 
between 95% and 107% of the prescribed dose, maintaining the dose to spinal cord 
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below 42Gy and the V20 as low as possible, as is routine in our clinical practice. The 
same beams were then applied to the other 5 PTVs. Small adjustments were made to 
beam size, gantry angle, wedge and beam weight where necessary to optimise these 
plans to the same standards.   
 
Data Analysis 
Cranio-caudal tumour motion was set as the cranio-caudal difference between 
geometric centre positions of the GTVs in the single phase-bins representing the most 
superior and most inferior tumour positions. 
 
The volumes of the PTVs and the toxicity parameters V20 lung, V5 lung, MLD and V50 
oes were noted in all six plans for each patient. The reductions in volumes and toxicity 
parameters between the 4DCT and the two RGRT plans with corresponding set-up 
margins were calculated. The correlation coefficient between the reduction in toxicity 
parameters and tumour movement was calculated using Pearson’s product correlation 
coefficient on Microsoft Excel 2002. The two-tailed t-test was used to check for 
statistical significance.  
 
 
 
 
 
 
 
 
 
 
 
 
 
6.3 Results 
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Fifteen patients, with node positive lung cancer were identified with >5mm of 
movement on the 4DCT planning scan. Tumour staging, location, cranio-caudal 
movement for all patients along with PTV, V20 and MLD from 4D_PTV (10mm margin) 
are presented in Table 6-1. In the pre-selection cine-movie process all patients 
demonstrated >5mm of movement in the primary tumour, but some of the cranio-
caudal movements noted using the geometric centre of the entire gross tumour were 
<5mm. This is mostly due to the incorporation in the GITV of the lymph nodes which 
move less than the primary tumour.  
 Dose and volume statistics are presented in Table 6-2. In the plans created using the 
margin of 10mm, the PTV delineated for inspiration RGRT [Insp_PTV (10mm margin)] 
and expiration RGRT [Exp_PTV (10mm margin)] were compared to the plan created 
using all phases of the respiration cycle [4D_PTV (10mm margin)]. The median 
reduction in V20 with inspiratory gating and expiratory gating was 2.0% (range 0.7% – 
3.9%) and 0.6% (range -1.1% to 4.7%) respectively; the reduction in V5 was 3.8% (range 
1.3% to 8.0%) and 1.0% (range -2.6% to 6.4%) respectively and the reduction in MLD was 
0.9Gy (range 0.2Gy to 3.2Gy) and 0.7Gy (range -0.1Gy to 2.7Gy) respectively.  
Similarly, with only a 5mm set-up margin, median reduction in V20 with inspiratory 
gating and expiratory gating was 2.4% (range 0.5% to 4.4%) and 0.5% (range -0.7% to 
3.6%) respectively; the reduction in V5 was 4.9% (range 1.2% to 8.7%) and 1.3% (range -
0.9% to 6.2%) respectively and the MLD reduction was 0.9Gy (range -0.1Gy to 3.9Gy) 
and 0.7Gy (range -0.5Gy to 3.2Gy) respectively. 
 
Figure 6-1 allows easy visualisation in scatter plots of the lack of correlation between 
the cranio-caudal tumour movement and both V20 and MLD. Table 6-3 shows the 
correlation coefficients between tumour motion and each toxicity parameter. The only 
toxicity parameter that showed a statistically significant correlation was between 
tumour motion and V5 in both the inspiration plans. All the other toxicity parameters of 
the lung showed no correlation.  
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The V50 oes is reduced by a mean of 2.1% (range 0% - 9.33%), 1.4% (range 0% - 9.0%) 
with inspiration and expiration RGRT using 10mm margins respectively. With the 
margins of 5mm the inspiration and expiration margin reduction was 1.6% (range 0% - 
6.6%), 1.0% (range 0% - 4.6%) respectively. The correlation between motion and 
reduction in V50 oes is a statistically significantly negative correlation in both the 
inspiration and expiration plans with the smaller margin, and fails to demonstrate any 
correlation in both 10mm margin plans, indicating that it is not the case that increased 
motion results in larger reduction in oesophageal toxicity.  
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Figure 6-1. Correlations between reduction in lung toxicity parameters and tumour 
motion in: (a) Insp PTV (10mm margin) (b) Exp PTV (10mm margin) (c) Insp PTV (5mm 
margin) (d) Exp PTV (5mm margin). 
 
(a) 
 
 
       
(b)  
  
   
 
(c) 
 
 
    
(d) 
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An additional observation of our study was that the reduction in toxicity parameters 
achieved by reducing the set-up margin, from 10mm to 5mm, during continuous (non-
gated) 4DCT treatment was actually larger than that seen with the addition of RGRT. 
This suggests that if a centre wished to reduce toxicities, there is more benefit to be 
gained by improved online verification which can reduce margins from 10mm to 5mm 
than introducing RGRT which is a complicated, work intensive technique that is only 
suitable for a minority of patients. Table 6-4 demonstrates the reduction of toxicity 
parameters when the margin is reduced versus the reduction when end-inspiration 
RGRT is used. 
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Table 6-1. Patient characteristics 
 
 
 
 
 
 
 
 
  
  
Tumour 
Stage 
Tumour 
Position 
Tumour Motion 
(cm) 
4D PTV [10mm 
margin] (cm3) 
V20 lung 
(%) MLD(Gy) 
  
  Patient 1 T4 N2 LLL 0.62 664.56 41.8 21.7   
  Patient 2 T2 N1 RML 1.47 359.10 18.0 10.2   
  Patient 3 T2 N1 RUL 0.34 331.09 16.7 10.8   
  Patient 4 T2 N1 RML 0.75 230.99 20.1 11.6   
  Patient 5 T2 N1 RML 0.17 588.92 48.0 25.0   
  Patient 6  T1 N2 LUL 0.69 615.54 28.3 14.8   
  Patient 7 T2 N1 RLL 2.08 1323.71 28.0 18.0   
  Patient 8 T4 N1 RLL 0.67 425.97 21.5 11.8   
  Patient 9 T2 N2 RUL 2.83 770.88 31.7 17.4   
  Patient 10 T2 N2 RLL 0.23 527.85 42.4 21.6   
  Patient 11 T3 N2 RUL 0.51 163.48 13.3 7.1   
  Patient 12 T2 N1 RML 1.12 197.01 22.9 12.4   
  Patient 13 T2 N1 RLL 1.23 818.79 20.9 12.6   
  Patient 14 T3 N1 RLL 0.35 573.28 31.3 16.8   
  Patient 15 T4 N2 RML 0.96 903.00 43.7 23.6   
         
        
Abbreviations: R, right; L, left; LL, lower lobe; UL, upper lobe; ML, middle lobe; PTV, planned target volume; 
V20, volume of lung receiving >20Gy; MLD, mean lung dose. 
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Table 6-2. Reductions of volume and toxicity parameters using RGRT compared with 
continuous (non-gated) 4DCT treatment. 
 
 
 
 
 
 
    PTV (cm3)   V20 Lung (%)   V5 Lung (%)   MLD (Gy)   
 
V50 
oesophagus 
(%) 
 
Mean 86.40  2.05  3.95  1.09  2.09 
SD 65.60  0.92  1.84  0.71  2.84 
Insp PTV  
(10mm 
margin) 
Range 16.58 - 242.15  0.72 - 3.86  1.29 - 8.00  0.22 - 3.20  0 - 9.33 
Mean 106.04  0.58  1.25  0.87  1.36 
SD 111.61  1.43  2.11  0.68  2.42 
Exp PTV  
(10mm 
margin) Range 26.78 - 460.62  -1.1 - 4.74  -2.59 - 6.44  -0.1 – 2.7  0 - 9.03 
Mean 69.39  2.26  4.25  1.17  1.61 
SD 56.07  1.20  2.16  0.95  2.22 
Insp PTV  
(5mm 
margin) Range 11.61 - 213.21  0.5 - 4.4  1.21 - 8.73  0.1 – 3.9  0 - 6.6 
Mean 83.21  0.70  1.63  0.97  1.03 
SD 92.34  1.10  1.83  0.53  1.38 
Exp PTV  
(5mm 
margin) 
Range 17.71 - 384.43   -0.68 - 3.61   -0.9 - 6.23   -0.1 – 2.3   0 - 4.6 
  
Abbreviations: SD, standard deviation; MLD, mean lung dose; PTV, planned target volume; Insp PTV, PTV created at Inspiration 
RGRT; Exp PTV, PTV created at Expiration RGRT. 
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Table 6-3. The correlation between tumour motion and toxicity parameters. 
 
 
 
 
 
      V20 Lung (%)   
V5 Lung 
(%) 
  
MLD 
(Gy) 
  
 
V50 oesophagus 
(%) 
  
  
 
Correlation between tumour 
motion and Insp PTV (10mm 
margin) 
 
 -0.06  0.60*  0.34  -0.37   
  
Correlation between tumour 
motion and Exp PTV (10mm 
margin) 
 -0.41  0.29  -0.06  -0.39   
  
 
Correlation between tumour 
motion and Insp PTV (5mm 
margin) 
 
 0.15  0.59*  0.43  -0.57*   
  
Correlation between tumour 
motion and Exp PTV (5mm 
margin) 
 -0.15  0.44  0.12  -0.57*   
 
          
  
* Indicates correlation is statistically significant with p = <0.05 
 
Abbreviations: V20, volume of lung receiving >20Gy; V5, volume of lung receiving >5Gy; MLD, mean lung dose; PTV, 
planned target volume; Insp PTV, PTV created at Inspiration RGRT; Exp PTV, PTV created at Expiration RGRT. 
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Table 6-4. Reductions of volume and toxicity parameters with the use of RGRT versus 
the reduction of set-up margins. 
 
 
 
    
 
PTV (cm3) 
 
V20 Lung (%) 
 
V5 Lung (%) 
 
MLD (Gy) 
 
V50 oesophagous 
(%) 
 
Mean 171.93 2.81 4.95 1.59 4.05 
SD 78.79 1.83 1.71 0.63 3.83 
 
Reduction in toxicity 
parameters from:  
 
4D_PTV (10mm margin)  
to 
4D_PTV (5mm margin) 
 
Range 73.9 - 357.8 -0.1 - 6.3 1.1 - 7.8 0.8 – 3.0 0.0 - 12.6 
Mean 86.40 2.05 3.95 1.09 2.09 
SD 65.60 0.92 1.84 0.71 2.84 
 
Reduction in toxicity 
parameters from: 
 
4D_PTV (10mm margin) 
to 
Insp_PTV (10mm margin)  
 
Range 16.6 - 242.2 0.72 - 3.86 1.29 - 8.00 0.22 – 3.20 0.00 - 9.33 
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6.3 Discussion 
 
With all the interest there is in RGRT and its implementation, it is a significant finding 
that we have demonstrated a very limited improvement of lung and oesophageal 
toxicity parameters with the use of RGRT in node positive lung tumours. There are 
numerous papers addressing the likelihood of radiation pneumonitis and thereafter long 
term lung damage, and equally as many papers calculating methods of predicting 
these, however there remains no consensus on what reduction of lung toxicity 
parameters, provides what reduction in likelihood of radiation pneumonitis 
[143,144,145]. To quantify the reduction in risk, we would need to select a paper at 
random and calculate this risk reduction using their NTCP models, for each individual 
patient, using each different plan. However there are widely felt concerns regarding 
the use of these models for an individual patient and therefore they must be used with 
caution [152]. Due to the lack of consensus on which model should be used, the 
concerns regarding these models in individual patients and the large quantities of 
further work required to calculate a model driven reduction of risk of radiation 
pneumonitis for each patient, this analysis was not carried out. Some might argue that 
any improvement in toxicity parameters is a step in the right direction. For example, in 
our centre, radical radiotherapy is withheld for patients with a lung V20 of 35% 
however individual clinicians may have different limiting parameters both in our centre 
and in other centres. In some patients, a small reduction from above to below the 
believed cut off may render a patient radically treatable within the strict confines of a 
protocol. However, out with the rigid limitations of protocols, one has to be sceptical 
whether a reduction in V20 of around 2% will reflect in a better clinical outcome for 
any patient. We feel that this is outweighed by additional potential errors and the 
significant additional time involved in implementation and treatment with RGRT. In 
view of the limited reduction in toxicity parameters, it is unlikely any of the three 
theoretical advantages of RGRT will be achieved.  
 
The challenge is to identify the minority of patients who would receive the most 
benefit from RGRT. Only one of the 15 patients (6%) had a reduction of V50 lung of >4% 
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and MLD of >4Gy. However we found no convincing correlation between tumour motion 
and toxicity parameters indicating that tumour motion cannot be used as a method of 
identification. This suggests that there is a complex combination of factors which 
determines treatment toxicity parameters e.g. tumour size, tumour location (extension 
into lung or solid tissue), tumour motion, treatment beam configuration and relative 
dose weighting per beam. Further investigation is required, to see whether it is possible 
to pre-select patients for RGRT. Failing that, comparative planning will be required on 
a patient by patient basis.  
 
There are two papers investigating this issue. Starkschall et al. found that only in small 
tumours (volume of GTV <100cm3) was there a correlation between tumour motion and 
improvement in V20 [91]. Direct comparison with our results is difficult for a variety of 
reasons: they reported the V20 reduction only as a ratio, and not with any absolute 
values; they only investigated end-expiration RGRT, which we found to be of less 
benefit; they used the same free-breathing scan for dose calculation of all plans; 
thirteen of their 20 patients had GTVs of <100cm3, which are likely to represent Stage I 
tumours, of which we had none due to deliberately omitting them, the reasons for 
which are discussed below. An additional difference is the planning techniques. 
Starkschall et al. based their analysis on a prescription of 60Gy to the 93% isodose. 
Treatment was with a 4 field technique. AP-PA fields were weighted to deliver 44Gy 
and lateral or lateral-oblique opposing fields delivered 16Gy. This creates a very 
different dose distribution than our 3-field technique. In their technique, lung tissue 
which lies only within the lateral fields cannot reach a dose of 20Gy whereas all lung 
tissue which lies within the AP-PA fields must inevitably receive in excess of 20Gy. The 
impact on V20 of treatment field size adjustment to account for target motion in the 3 
principal axes would be quite different in the 2 techniques. Underberg et al. performed 
a similar study looking at the benefit of gating in 15, Stage III NSCLC patients [92]. The 
PTV sizes were comparable to ours however the motion of the tumour in our study was 
marginally more as we specifically selected patients with more motion. They compared 
a number of different plans, but those of interest for comparison are the plans created 
from the volumes encompassing all motion versus an end-expiration gate. It is 
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reassuring they demonstrated similar small reductions in toxicity parameters with an 
absolute reduction in MLD and V20 of 0.9Gy and 1.9% respectively. 
 
There is some suggestion in the literature that RGRT can be used in Stage I tumours 
with stereotactic radiotherapy [153], however the three theoretical benefits of RGRT 
have already been achieved by the development of standard stereotactic radiotherapy 
[12,13,14]. This technique has limited toxicity, can deliver biological equivalent doses 
of 180Gy with excellent local control rates, and all patients are eligible as the volumes 
in Stage I tumours tend to be small. Consequently, reducing the volumes and hence the 
toxicity parameters in Stage I tumours may not be a worthwhile exercise hence, our 
study concentrated on node-positive lung cancers where the theoretical benefits of 
RGRT have not yet been achieved by other technologies.  
 
There was an additional observation that reducing the set-up margin from 10mm to 
5mm provides a larger reduction in the V20 than RGRT. This raises the question as to 
whether the emphasis in radiotherapy departments should be to improve set-up errors 
using on-board imaging rather than implementing RGRT. Both techniques involve 
increase in work intensity however, online verification techniques can be used for all 
patients where as RGRT is only useful in a minority of patients. Therefore if a centre is 
to implement a technique to decrease toxicity, an online verification technique would 
provide a bigger decrease. 
 
Comparing the benefit of Expiration RGRT versus Inspiration RGRT, we have shown that 
gating has a greater effect on toxicity parameters at end-inspiration. This would be 
consistent with the assumption that the lung volume is expanded and greater sparing is 
possible. Table 6-2 highlights the very marginal improvements at end-expiration. The 
authors feel that should RGRT be applied, end-inspiration is recommended, with an 
awareness of its problems. However this cannot be applied indiscriminately to all 
patients and it may be appropriate to assess the possible improvements on a patient by 
patient basis with computer comparison of gating versus continuous (non-gated) 4DCT 
treatment.  
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In conclusion, there is a great deal of interest in RGRT and its development in 
radiotherapy centres worldwide, however this study demonstrates that the vast 
majority of patients are unlikely to have a better clinical outcome with RGRT 
treatment. Due to the additional potential errors involved in RGRT, we feel that until 
further investigation identifies a good method of selecting patients for RGRT, it should 
only be performed if comparative planning of RGRT plans and continuous (non-gated) 
4DCT plans has been undertaken and a likely clinical benefit has been confirmed.  
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7. CONCLUSIONS. 
 
The conclusions to each individual study have been discussed in each chapter in turn. 
There are a number of issues that the thesis as a whole highlights which will be 
discussed below.  
 
This thesis demonstrates how IGRT involves the integration of imaging techniques in all 
three of the stages of radiotherapy; delineation, verification and treatment delivery. In 
addition, the thesis also highlights that each stage has many different imaging 
techniques that could be used, usually in combination. For example, in verification, it 
is apparent that each imaging technique is more suited to identifying and limiting 
different types of potential error; MV cine-images are useful for intrafraction tumour 
motion, while CBCT is the best imaging modality to highlight any significant 
interfraction tumour motion over the treatment course. The ideal would therefore be 
to use the different imaging techniques in combination. The challenge in future 
investigations of IGRT is to identify the combination and timing of different images to 
maximize tumour coverage and minimise irradiation of normal tissues. One of the 
hypothetical aims of this thesis was to ensure IGRT could be implemented into a busy 
clinical department. As a result, investigation into the minimal number of each imaging 
technique would be a useful research avenue to minimise the impact on clinical 
departments. 
   
It is apparent that for most technologies used within IGRT, other than SBRT, that there 
is no clinical outcome data. In IGRT, surrogates such as improved target coverage or 
decreased toxicity parameters are used. Primarily, this is because these newer imaging 
techniques address potential errors we were not capable of visualising or quantifying 
before. Trials comparing current IGRT techniques with previous methods would be 
considered unethical by many, as we would be treating patients while aware there are 
preventable errors. As a result, once a centre has confirmed improved target coverage 
and reduced normal tissue toxicity, departments are happy to implement them into 
clinical care without clinical outcome data. In addition, without implementing IGRT it 
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is impossible to begin to use other radiotherapy technologies, such as IMRT or SBRT 
which do have good published outcome data. We hope that with the implementation, 
auditing and continuous improving of appropriate IGRT technologies, we will see an 
improvement in local control and overall survival over the coming years. 
 
The different outcomes of the different chapters emphasise the need to critically 
analyse any new technique. RGRT and AMTD are two different techniques that are 
implemented and studied. The study in chapter 6 examining AMTD is an initial report 
confirming there are only a small number of patients whose tumours occasionally move 
out with the PTV delineated. It requires further investigation, initially to compare the 
technique to standard delivery of radiation throughout the respiratory cycle and 
laterally to assess the potential clinical benefit. As discussed above, the outcomes of 
these studies will likely be surrogates of clinical outcome, due to the difficulties of 
using clinical outcome as an endpoint. The RGRT study, suggested there was a minimal 
reduction in toxicity parameters and therefore had limited clinical benefit to the 
majority of patients. Both of these studies affirm the need to study and publish results 
on new techniques once they have been implemented to confirm they offer some 
improvement on current techniques.  
 
Lastly, during these investigations, it is evident that radical radiotherapy for lung 
cancer should be tailored to each patient. It is not appropriate to have one method of 
treatment for all. The gating study highlights that although RGRT can offer a reduction 
in toxicity for a few patients, it is not clinically relevant for a vast majority. The 
delineation study is in accordance with this finding as it finds the MIP image from the 
4DCT scan can be used in those with Stage I tumours but is not appropriate for those 
with node positive disease.  A further avenue for research in IGRT is how to tailor our 
new techniques to patients those who stand to gain the most from them. New 
techniques must be investigated in specific homogenous patient groups so that 
conclusions identify whether or not they are applicable in that patient group.  
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In summary, the era of IGRT is in the early stages. There is so much new technology 
available, but significant careful further study is required to ascertain more regarding 
the role of some techniques and how to implement them into clinical care. Further to 
that, the challenge is to identify the most appropriate combination of imaging 
techniques for each individual, in order to achieve the best clinical outcome for every 
patient.  
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